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ON THE COVER
On the cover is a photograph of a section of
healthy mouse hippocampus tissue (near the
dentate gyrus) at 30 days of age. The tissue is
stained for nuclei (blue), astrocytes (green), and
glucose transporter GLUT8 (red). The image was
produced during research conducted by Madhuri
Rao, MSII.
Photos like Rao’s, capturing the beauty and
intricacy of science, are featured annually in the
George Washington University (GW) School
of Medicine and Health Sciences (SMHS) Art
of Science Contest. The competition began in
2018 as a means of highlighting the research that
SMHS medical students, graduate students, and
postdoctoral fellows are conducting.
This year, more than 17 images were submitted,
an increase from last year’s competition, and fve
entries were chosen as winners.
A grand prize of $250 was awarded to Brett
Eaton, a PhD student who submitted an image of
the Marburg virus budding from infected dendritic
cells. Prizes of $100 were awarded to four other
entrants, all GW PhD students — Rachel Burga,
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Samantha Dow, Naemeh Pourshafe, and Jessica
Schenck.
The winning images will be displayed in Ross
Hall, alongside the winners from last year.
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A s pa r t of t he G eorge
Wa s h i n g t o n Un i v e r s i t y
(GW ) School of Medicine
and Health Sciences’ (SMHS)
mission to educate, research,
and heal, GW medical students have the opportunity to
conduct research in a multitude of felds. The William H.
Beaumont Medical Research
Honor Society aims to promote inquiry-based research
to train physician-scientists for
the future. This journal, run
by the William H. Beaumont
Society, is an entirely studentr un publication including
research conducted by GW
medica l students while in
medical school. This year’s
collection of abstracts refects
a sample of the diverse student
research being conducted at
SHMS from basic science to
clinical research to public
health initiatives.
As co-presidents of the
William H. Beaumont Medical
Research Honor Society, we
aim to provide a forum to learn
about peer research, inspire
future and matriculating medical students, and serve as an
outlet to share research experiences of GW
medical students. We hope that this journal
inspires a dialogue to continue the sharing
of new knowledge and passion for research

amongst our students, faulty, and staf. We
aim to support GW’s goal to expand and
enhance research experiences for its students
as an opportunity to learn and become future
leaders in medicine and health sciences felds.
We would like to ofer our congratulations
to this year’s William H. Beaumont Medical
Honor Society Student Research Award winners. These individuals and their research
projects stood out as exceptional in quality
among their peers.
This year’s edition would not have been possible without the support of many individuals.
We would like to thank former presidents,
Janine Amirault and Sarah McCormack, for
their continued involvement and support of
this organization. We would like to thank
our faculty adviser, Dean Alison Hall, for her
wisdom and support. We would also like to
thank the SMHS Ofce of Communications
and Marking for the design and production of this year’s edition. Finally, we would
like to thank our classmates and peers who
volunteered their time to edit the abstracts
submitted, without whom this journal could
not exist.
On behalf of the William H. Beaumont
Medical Research Honor Society’s executive
board and members, we hope you enjoy the
2019 edition of Fusion!

Neil Almeida, MSII
Abby Pepin, MSII
Co-Presidents of the William H Beaumont
Medical Research Honor Society
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Letters:

From the Faculty Adviser:
It’s an honor to assist with this edition of
Fusion magazine that highlights research done
by medical students at the George Washington
University (GW) School of Medicine and
Health Sciences.
You will fnd examples of the broad range of
research pursued by students, from basic biomedical discovery to clinical and translational
research with patients to initial translation to
practice and communities, on every page of
Fusion. In their submissions, medical students
described numerous sophisticated approaches,
including chart review, data collection, molecular biology techniques, feld studies, study
design, assisting in IRB applications, and statistical analyses to name just a few. It is always
a challenge to select the abstract winners from
a collection of such excellent projects.
I would also like to thank the research
mentors who host students in their programs
here at GW and in our partner institution
Children’s National Health Center, and in
research programs at the nearby NIH campus
and other institutions around the nation.
Mentorship is key in engaging students and
encouraging research careers in academic
health centers.
Medical students have rich opportunities
for involvement in research. About 20 percent

LETTERS

of each class joins the clinical
and translational research
scholarly concentration, that
includes longitudina l lectures, summer research with
an abstract and poster, and
additional elective clerkships
in research. But you don’t have
to be in the scholarly concentration to do research! Many
students compete for external
research fellowships as well as
internal WT Gill and Health
Services Research summer felAlison K Hall, PhD
lowships. Students are encouraged to present — and to learn
— at GW’s Research Days in
April each year.
Fusion magazine is just one efort by the
William H. Beaumont Research Honor
Society to engage GW medical students in the
excitement and impact of research. I welcome
you to explore p. 4–5 and for additional ways to
join this community of clinician-investigators.

Alison K. Hall, PhD
Associate Dean for Research Workforce
Development, Professor of Neurology
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GW MEDICAL STUDENT RESEARCH

Numerous Opportunities for Medical Students to Engage in Research + Scholarship
RESEARCH SCHOLARLY
CONCENTRATION

32
Last year, 32 MD students elected
to join the Clinical and Translational
Research Scholarly Concentration.
In this program, students conduct
mentored research over the
summer between frst and second
year, attend research lectures, and
continue with research scholarships.
For details, see https://tinyurl.com/
ybpn74cl.

YEAR-OUT

Stephen Langerman is taking the 2018–19
year off to conduct research as part of the
National Institutes of Health (NIH)-Medical
Research Scholars Program. He will study
the infuence of social
factors, such as crime,
poverty, and discrimination on health
outcomes with Tiffany
M. Powell-Wiley, MD,
MPH, who heads the
Social Determinants
of Obesity and
Cardiovascular Risk
Laboratory at NIH.

Taniya Walker, MSII, won a 2018 Gill Fellowship to
conduct cardiology research on the effects of computed
tomography scan fndings on the outcomes of
transcatheter aortic valve replacement

GW RESEARCH FELLOWSHIPS
A number of competitive scholarship
programs are available to assist in
funding exceptional projects in health
care and medicine. In 2018, 31 students
won a Gill Summer Research Fellowship
and 57 students won a Health Services
Scholarship. For details,see
https://tinyurl.com/ybu4z3w5 and
https://tinyurl.com/y8ltewa9.

RESEARCH DAYS AT GW
GW Research Days is an April annual event that celebrates research
across GW. Students and postdoctoral fellows present posters and oral
presentations and compete for cash prizes.
See https://researchdays.gwu.edu/.

At Research Day 2018, Nicole Casasanta, Sarit Toltzis, Dara Baker, and Christina Pugliese accepted the
William Beaumont Research Award from former Fusion editors, Sarah McCormack and Janine Amirault
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FUSION
Fu s ion is GW ’s
annual medical
s tudent research
journal. It is a forum
to share research
done by GW medical
students with the
larger research
c o m m u ni t y. I n
2019, 35 s tudent
research abstracts
were published. The
Beaumont Society
seeks Fusion editors
each year.
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EXTERNAL FELLOWSHIPS
Medical students may elect to take a year off from the MD program
to conduct research full-time at GW, NIH, or other institutions. This
can be a great way to fully immerse yourself in a research project
and form connections at other institutions. External fellowship
opportunities are listed at https://tinyurl.com/y9vj54gj.
Third-year SMHS MD student Maggie Beatson, at left, is a Brown University
Dermatoepidemiology Research Fellow, studying predictors of skin cancer

METEOR PROGRAM

WILLIAM H. BEAUMONT
RESEARCH HONOR
SOCIETY
The Beaumont Research Honor
Society was established to
educate and inform medical
students about research. Any
GW medical student interested
in research is welcome to
join. 2018-2019 Co-Presidents
are Neil Almeida and Abby
Pepin. See https://tinyurl.com/
y7yuwr6w

...........

CTSA
The Clinical and
Translational Science
Award (CTSA) is a joint
NIH award between GW
and Children’s National
Health System to conduct
“bench to bedside”
research.

The Mentored Experience to Expand Opportunities in
Research (METEOR) program is a competitive fellowship
for underrepresented-in-medicine
students. Students
are supported
for a prematriculation
research
summer and
enroll in the
research track.
https://tinyurl.
com/y86oxwmb
METEOR students Guido Pelaez, MS1,
and Juan Nogues, MSII

ART OF SCIENCE IMAGE CONTEST
Students submit artistic images
of their research for cash prizes.
The award highlights the
breadth and beauty of research

done at GW. Aslam Akhtar,
MSII, was last year’s grand prize
winner. See https://tinyurl.com/
ybr8l26g

TRAVEL AWARDS

RESEARCH PRIZES
The 2018 Walter Freeman Research
Award for best research paper
was presented to (from left) Jason
Chien and Peter Mullins by Lorenzo
Norris, MD.

The 2018 Doris DeFord Speck
and George Speck Endowed
Prize was awarded to Laura
Tiedemann (at right) for her
research on neonatal intensive
care management.

Medical students are
encouraged to apply
for outside funding
for summer or yearout research, or for
travel to meetings.
Visit the Scholarly
Concentration website
to see a list of opportunities for summer
research, travel, and
yearlong fellowships.
See tinyurl.com/
y9vj54gj

To learn more, please contact the Office of Student Professional Enrichment smhs.gwu.edu/ospe.
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Evaluation of Longitudinal Antibody Responses in ZikaInfected Individuals from Colombia
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Since the Zika epidemic in 2015,
there have been striking associations
between Zika virus (ZIKV) infection and neurological complications,
sequelae which are most devastatingly seen in fetal development.1,2 As
a result, there is an urgent need for
a vaccine against Zika. However, in
order to elicit protective, neutral-

EC50 (Reciprocal Serum Dilution)

Maria Abigail
Cerezo, MSII

• EC50 1yr
• EC50 2yr

100,000
10,000
1,000
100
10
1

Time Point

FIGURE 1: Comparison of antibody titers from patients in Colombia, South America, at
one and two years post-Zika infection Titers were evaluated through indirect ELISA assays
The reciprocal plasma dilution at which binding was at 50% is graphed (EC50) This plot
depicts a gradual waning of the memory antibody response found within the plasma

Dengue and Zika neutralizing antibodies than those who did not develop
GBS during Zika infection.3 This
study hypothesizes that in regions
endemic for flavivirus
infection, individuals
We found that FL responses were signifcantly
who developed GBS and
had high neutralizing
stronger in people who did not develop GBS,
antibody titers will have
antibodies that target
and that DIII responses were undetectable
diferent viral epitopes
from those who do not.
in all patients.
To conduct this study,
clinica lly diagnosed
plasma samples taken
from Zika-infected persons living
izing antibodies there is a critical
in Colombia, South America, were
need-to-know of how pre-existing
tested for the presence and strength
immunity to Dengue virus afects the
of memory antibodies at two diferent
antibody response to Zika infection.
time points after virus clearance. Sera
We have previously observed that
were collected at one year (mean 1.3
people who developed Guillain-Barre
years) and two years (mean 2.3 years)
syndrome (GBS) had higher titers of
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EC50 2yr

EC50 1yr

post-Zika infection and were tested
against the ZIKV E (envelope) protein. As expected, all serum samples
bound highly to ZIKV E monomer
protein with detectable waning in
titer over one year (Figure 1). In order
to map the targeted viral epitopes,
we ran competition ELISAs using
known monoclonal antibodies, 4G2
and ZK67. These antibodies target
the fusion loop (FL) and Domain
III (DIII) of the E protein respectively. Interestingly, we found that
the majority of sera contained antibodies targeting the FL but not DIII.
Therefore, we investigated whether
there were clinical differences in
people who did or did not develop
Guillain-Barre syndrome (GBS). We
found that FL responses were signifcantly stronger in people who did not
develop GBS, and that DIII responses

Fusion ♦ 2019

were undetectable in all patients
(Figure 2). Our future direction is to
expand this dataset to map epitopes
found on the ZIKV E dimer, which
will better refect the natural conformation of ZIKV E protein.

% competition at 1:20 plasma dilution

100

REFERENCES
1.
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Antibodies Are Associated with GuillainBarré Syndrome. The Journal of infectious
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FIGURE 2: Graphs of Plasma Binding Competition to Zika E Monomer Protein with
Two Known Antibidies The percent binding competition to E protein at a plasma dilution
of 1:20 is graphed to (A) anti-fusion loop antibody 4G2 and (B) anti-DIII antibody ZK67
Each dot represents an individual plasma and is graphed by disease status of having a
diagnosis of GBS or Zika infection alone There is signifcantly less competition (fusion
loop antibodies) in the plasma from patients diagnosed with GBS by Mann-Whitney
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Prevention of Cardiovascular Thrombosis
Through Inhibition of Coagulation Factor XII

Discover y of an antithrombotic
therapy that does not cause bleeding
would be a transformative advance in
the management of conditions such
as myocardial infarction, stroke, and
venous thromboembolic disease. 1
One promising approach is inhibition
of factor XII (FXII/FXIIa), which
has been demonstrated to be thromboprotective in preclinical models.2
Importantly, severe congenital FXII
deficiency is not associated with
bleeding and FXII inhibition does
not augment bleeding in animal
models.3-4 Despite its potential as a
therapeutic target, the physiological
mechanisms of FXII recruitment to
sites of injury and its activation by
platelets remains poorly understood.5
To explore the binding and activation
of FXII by platelets during thrombus
formation, we stimulated platelet rich
plasma with PAR-1 agonist peptide
SFLLRN and measured the thrombin
generating capacity of platelets by
cleavage of a fuorogenic substrate in
the presence of anti-FXIIa antibody,
anti-TF antibody, and anti-FVIIa
antibody. We also stimulated washed
platelets with SFLLRN and tested
the ability of the various platelet
fractions, including from a patient
with Hermansky Pudlak Syndrome
(HPS), to generate thrombin and
FXIIa. Sim i la rly, we measu red
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platelet-dependent FXIIa generation in the presence of CaEDTA, a
specifc zinc chelator, to test whether
zinc was required for FXII binding
and activation. We next interrogated
whether phosphatidylserine (PS),
a negatively-charged phospholipid
expressed on the surface of stimulated
platelets, was responsible for FXII
activation using lactadherin, a phosphatidylserine blocker, and liposomes

FIGURE 1: Platelet-based thrombin
generation is FXXII-dependant Plateletrich plasma was stimulated with 50 μM
of the PAR-1 agonist peptide SFLLRN
(SF), and thrombin generation at 60
minutes was measured by cleavage of
a furogenic substrate in the presence
of (A) X210-C01, (B) anti-TF antibody,
and (C) anti-FVIIa antibody These
results demonstrate that stimulated
platelets can actively support thrombin
generation via a FXII-dependant
pathway ** p <0 05 compared to
control by Kruskal-Wallis with Dunn’s
post-test

containing increasing concentrations
of 80% phosphatidylcholine and 20%
phosphatidylserine (PC/PS). We used
platelet fow cytometry with FITClabeled FXII, bead-immobilized
immunoprecipitation, and mass spectrometry to investigate a potential
platelet binding partner for FXII. We
found that stimulated, but not resting
platelets, are able to support thrombin
generation via a FXII-dependent

Fusion ♦ 2019

FXIIa Generation (RU)

pathway (Figure 1). We demonstrated
that the FXIIa-generating capacity of
platelets is contained in the insoluble
fraction, not the releasate (Figure 2).
Evaluation of the interaction between
FXII and the platelet surface by fow
cytometry showed that FXII-FITC
binds to stimulated platelets in a specifc manner requiring cationic zinc.
Platelet-dependent FXIIa generation was inhibited by the presence of
CaEDTA (Figure 3). We found that
PS blockade with lactadherin prevents
platelet-dependent FXIIa generation,
while the addition of PS-containing
liposomes to plasma did not trigger
FXIIa production (Figure 3). These
results suggest that PS is necessary
but not sufcient for FXII activation
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Continued fom p. 9
and that another platelet surface
constituent is required. Using coimmunoprecipitation of FXII with
binding partners from platelet lysate
followed by mass spectrometry, we
identifed candidate platelet surface
proteins that bind with FXII in the
presence of zinc. Factor XII binds
the platelet surface in a specific,
zinc-dependent manner, which is
followed by its activation in a process
that requires PS. Together, these
results may explain the longstanding
clinical observation that platelets are

crucial for arterial thrombosis but
relatively less important in venous
clotting. Greater insight into this
mechanism would help address an
important scientific question and
aid in the much-needed development
of antithrombotic medications that
carry minimal risk of hemorrhage.

T. Targeting Coagulation Factor XII
Provides Protection from Pathological Thrombosis in Cerebral Ischemia
Without Interfering with Hemostasis. J
Exp Med 2006;203: 513-8.
3.
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CyTOF Analysis Provides Insight into Immune Response to
H3 327M Neoantigen Peptide Vaccine in Glioma Patients

Gliomas are the most common brain
tumor found in children and comprise
half of all pediatric central nervous
system (CNS) tumors.1 Difuse midline glioma, H3 K27M-mutant is a
novel entity describing a classifcation
of tumors of the CNS, predominantly
arising in pediatric patients, located
within midline structures, and carrying a poor prognosis. K27M mutations in H3F3A or HIST1H3B/C,
encoding the histone variants H3.1 and
H3.3, have been shown to be critical
for gliomagenesis. 2 The Okada lab
recently implemented a trial in which
newly diagnosed children with difuse
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FIGURE:
midline glioma who are positive for
HLA-A2 and the H3.3K27M mutation
that underwent radiation therapy,
received a specifc H3.3K27M peptide

vaccine, combined with the tetanus
toxoid (TT) peptide, emulsified in
Montanide. Poly-ICLC, which is a
Toll-like receptor 3 agonist, was given
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concurrently to improve the therapeutic efects of the vaccine. Vaccine
was administered every three weeks
for the first 24 weeks. If there was
stable or improved disease, vaccine
was administered every 6 weeks for a
total treatment period of 96 weeks. My
objective was to develop an immune
evaluation system to gain insight into
immune response to H3.327 peptide
vaccine. Peripheral blood mononuclear cells were obtained at each
of these time points and analyzed
utilizing mass cytometry (CyTOF).
CyTOF is an emerging single-cell
analysis platform that uses atomic
mass spectrometric analysis to quantify up to 42 metal-tagged antibodies
per cell. The large number of analytes
per cell allows the simultaneous monitoring of multiple immune subsets

from small tumor samples, making it
ideal for this clinical trial. Dextramer
technology involves utilizing heterogenous polymers conjugated to MHC
molecules that bind to T-cells and
can subsequently be detected using
CyTOF.
Control T-cells and K27M TCR
transduced T-cells were treated with
dasatinib to reduce TCR internalization and subsequently stained with cisplatin. This was followed with staining
with H3.3 dextramer with conjugated
PE fuorophore and metal conjugated
CD3 (141Pr). H3.3 dextramer-PE was
detected on CyTOF using anti-PE
monoclonal or polyclonal antibody
conjugated 173Yb. These preliminary
results indicate that TCR-specifc T
cells can be detected using dextramerPE and metal conjugated anti-PE

BEAUMONT RESEARCH PRIZE WINNERS

monoclonal antibody with minimal
non-specifc staining. Furthermore,
this validated the efcacy of utilizing
dasatinib as a method of increasing
TCR cell surface expression. This will
serve as a powerful tool to learn about
how the anti-tumor immune response
could be activated and the impact
of tumor microenvironment on the
functional status of vaccine-induced
T-cells both systemically and locally.
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gene expression trends elsewhere in
the genome, elucidating functional
relationships between gene variants
and gene expression.
Our pipeline starts with clustering
in Graphia Professional, which uses
a graph-based approach to build
relationships between genes.3,4 Each
VAF or gene expression “time-course”
groups with another if it meets a
minimum Pearson correlation of
0.96. As a result, genes with similar
expression trends and VAF trends
are connected to each other in a
structured graph (Figure 2). We then
used a machine learning method
called the Markov Cluster algorithm
(MCL) to partition the graph into
formal clusters by looking for packs
of highly interconnected genes.5 We
then built custom R modules to scan
through the clusters to fnd pairs of
VAF and gene expression profles that

>-i

A Machine Learning Approach to Mapping Co-regulated
Variant Loci and Gene Expression over Time

Vl
----

Arjun Panda,
MSII

FIGURE 1:
the Horvath lab has tackled using a
novel metric called the Variant Allele
Frequency (VAF).2 The variant allele
frequency (VAF) measures the RNA
expression of SNV-containing loci
(VAFRNA = nvar / ( nvar + n ref )), where
nvar and nref are read counts containing the variant and reference SNV
(Figure 1). Whereas a DNA allele
count can model the efect of a discrete dose of variant harboring alleles
(N ∈ {0,1,2} for diploid genomes) on a
phenotype such as transcription, the
VAF is a continuous measurement
with a support of N ∈ [0,1]. Thus the
VAF accounts for the true allelic prevalence at multi-allelic loci and refects
molecular regulation events such
as imprinting, post-transcriptional
regulation by RNA binding molecules, as well as RNA editing. From
here, we needed to see if temporal
VAF regulation mirrored absolute

~
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We developed a machine learning
analysis pipeline to discover functional gene variants by examining
the efect of RNA containing single
nucleotide variants (SNVs) on gene
expression at cis- and trans- genomic
locations over time. This refects a
hypothesis of genetic co-regulation
where, as the relative presence of a
particular variant allele seen in RNA
transcription changes over time
(due to changing cellular requirements), gene expression elsewhere
in the genome is afected as a result
(Figure 1). We believe this analysis
pipeline can give novel mechanistic
insights into a wide range of basic and
translational cell biology questions,
particularly on the evolution of drug
resistance in cancer cells.
In order to measure changing
cellular requirements in cancer cell
lines, we conducted paired-end RNA
sequencing on human melanoma cell
line WM164 under four experimental
conditions: with and without histone
deacytelase (HDAC) inhibition, and
with and without IFN-gamma treatment. This was done over eight time
points each, for a total of 32 samples.
We then aligned the RNA-sequencing
reads to the human genome and called
variants.1
Measuring the reg u lation of
variant containing RNA is a problem
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RNA Variant Allele Freq.
Gene Expression

cluster together in two samples or
more. Once found, each pair was categorized as a cis- relationship if they
were less than one million base-pairs
apart, and trans- otherwise.
All 60,963 VAF and gene expression profles were clustered into 3,730
clusters, where each cluster represents
a certain pattern of RNA regulation
through time. Using custom R scripts,
we discovered 440 co-reg ulated
VAF containing positions and gene
expression profles. Further work will
include Protein-Protein Interaction
(PPI) analyses to validate fndings,
especially in a larger data set.
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It is well established that muscle and
bone have a rich and complex biomechanical relationship. In particular,
according to the mechanostat hypothesis, bone growth and bone loss are
stimulated by the local mechanical
elastic deformation of bone. Thus,
bone mineral density (BMD) increases
in response to muscle use and strengthening due to increased load-bearing of
the afected bone.1 Originally, it was
thought that the strain of the muscle
on the bone was the primary impetus
causing the increased BMD, however, more recently, researchers have
concluded that a paracrine/endocrine
relationship between muscle and
bone is the more likely explanation.
From the onset of life, muscle and
bone cells are highly similar due to
their common mesodermal origin.2
At the height of their development,
these tissues make up the majority of
our body mass and exhibit complex
endocrine relationships with the rest
of the body.3 While the proteins that
are secreted from muscle and bone are
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to be signifcantly associated with the
well described, the genetic variants
muscular phenotypes in each cohort.
that infuence these relationships are
This expectation was confirmed
not fully understood. In this study,
using an additive model in Caucasian
we focused on two single nucleotide
females from the AIMMY cohort for
polymorphisms (SNPs) (rs1889018 and
right hand grip strength; however, this
rs7501812) found in genes SREBF1 and
fnding was not extended to the other
TOM1L2, respectively. Our goal was
cohorts. TOM1L2 is often studied
to explore their individual and possible
in conjunction with SREBF1 as they
pleiotropic efects on bone and muscle
share a locus. Our data confrm the
phenotypes in one cohort of African
impact that TOM1L2 rs7501812 has on
American children (Bone Health) and
a variety of phenotypes including total
two cohorts of young adults (FAMuSS
body BMD, grip strength, VO2 max
and AIMMY).
and baseline 1-repetition maximum
All cohorts were genotyped using
strength in more than one cohort
the Applied Biosystems Taqman
and in both Caucasians and African
allelic discrimination assays and the
Americans, thus meeting our expectaQuantStudio 7 Flex Real-Time PCR
tions based on the existing literature.
System. After testing for HardyThe pleiotropic features of TOM1L2/
Weinberg equilibrium (HWE), data
was stratified by
sex and cohort and
The role of SREBF1 has been well described in
a na lyzed using
analysis of covarirecent literature as a regulator of myogenic reguance (ANCOVA)
applying both an
latory factors (MRFs) and causes muscle atrophy
additive and dominant model. Where
when overexpressed both in vivo and in vitro.
appropriate, post
hoc pair-wise comSREBF1 have been explored in conparisons were performed and the
junction with other loci affecting
resulting p-values adjusted for multiple
BMD and lean mass.5 In this study,
comparisons using the Sidak method.
we found that the two SNPs had a
For the SNP-SNP interaction analstatistically significant pleiotropic
ysis, linear regression models were
relationship with the phenotypes
used and included gender, appropriate
VO2 max and bone volume of the noncovariates, and an interaction term
dominant arm in the FAMuSS cohort,
quantifying the number of minor
while the relationship in the dominant
alleles present for each SNP pair.
arm approached signifcance.
The role of SREBF1 has been well
described in recent literature as a reguREFERENCES:
lator of myogenic regulatory factors
1. Sugiyama T, Yamaguchi A, Kawai S. Efects
(MRFs) and causes muscle atrophy
of Skeletal Loading on Bone Mass and
when overexpressed both in vivo and
Compensation Mechanism in Bone: A New
in vitro. 4 Based on this finding, we
Insight into The “Mechanostat” Theory. J
expected the SREBF1 SNP rs1889018
Bone Miner Metab. 2002;20(4):196-200.
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Genetic variants in the muscle-specific gene FAM210A (rs4796995),
and the bone-specific gene SOST
(rs4792909), which codes for the osteokine sclerostin, have been shown to be
associated with total BMD and fracture risk. FAM210A knockout mice
have low grip strength, as well as high
levels of matrix metalloproteinase-12
(MMP-12), a bone-resorption related
peptide. Sclerostin suppresses the
Wnt/b-catenin signaling pathway in
osteoblasts and osteocytes by binding
to LRP5/6 coreceptors, thereby inhibiting osteoblast development. The
purpose of this study is to explore the
infuence of these genetic variants on
musculoskeletal phenotypes in three
previously developed cohorts.
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Cohorts: AIMMY: 153 Caucasian
young adults aged 18-35 (82 M, 71 F; avg.
age 23.2 yrs) and 75 African American
young adults aged 19-25 (21 M, 54 F;
avg. age 19.2); FAMuSS: 368 young
adults (135 M, 233 F, avg age 23); Bone
Health: 73 healthy African-American
children, (38 male, 35 female; ages 5-9)
Phenotypes: AIMMY: right and left
arm grip strength, maximal oxygen
consumption (VO2 max), and body
mass index (BMI). FAMuSS: baseline isometric strength and 1-RM
strength in the non-dominant (ND)
and dominant (D) arms, and total
bone and cortical humeral bone volumes. Bone Health: height-adjusted
tota l BMD minus head z-score.
Genotyping: Applied Biosystems
Taqman allelic discrimination assays
and the QuantStudio 7 Flex RealTime PCR System were used to perform genotyping. Statistical Analysis:
Hardy-Weinberg equilibrium was
assessed. Phenotypes were tested
in gender specific cohorts using
ANCOVA, where phenotype was
the independent variable, genotype
was the dependent variable, and
weight and/or age were covariates.
Post hoc pair-wise comparisons were
performed and the resulting p-values
adjusted using the Sidak method. For
the SNP-SNP interaction analysis,
linear regression models were used
and included gender, appropriate
covariates, and an interaction term
quantifying the number of minor

alleles present for each SNP pair. IRB:
This project was approved by the IRB
of the Children’s National Health
System and the University of Calgary.
SOST was found to be out of HardyWeinberg equilibrium in the FAMuSS
(p=0.034), Bone-Health (p=0.006),
and AIMMY cohorts (p<0.001).
Among men of FAMuSS, statistically
signifcant associations were found
between variants of FAM210A and
D arm baseline bone+marrow volume
(p=0.006), D arm baseline cortical
bone volume (p=0.001), and ND
arm baseline cortical bone volume
(p=0.009) using an additive model.
Statistically signifcant associations
were found between FAM210A and
the right (p=0.022) and left (p=0.007)
grip strengths of African-American
women of AIMMY. Caucasian males
of AIMMY were found to have a
statistically significant association
between VO2 max and FAM210A
in both the additive (p=0.037) and
dominant (p=0.002) models. No
significant association was found
b et we en FA M 210A t he B one Hea lt h phenot y pes. SN P- SN P
interaction analysis between SOST
and FAM210 showed statistically
signifcant interactions in FAMuSS
on ND arm baseline 1-RM strength
(coefficient=0.567, p=0.046) and
N D a rm baseline cortica l bone
volume (coefcient=352, p=0.040). A
Continued on p. 16
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Continued fom p. 15
statistically significant interaction
was also found in the Caucasian
subgroup of AIMMY in VO2 max
(coefcient=1.529, p=0.037).

Early identifcation of individuals
at risk for developing lower peak bone
mass and possibly increased fracture
risk as seniors has the potential to
set the stage for the development of
personalized medicine protocols/

inter ventions designed to reduce
long term fracture risk by helping
these individuals maximize the use
of appropriate ftness, nutrition, and
other health maintenance strategies.

Programmed Death Ligand 1 Is a Negative
Prognostic Marker in Recurrent Isocitrate
Dehydrogenase-Wildtype Glioblastoma
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The glioblastoma microenvironment is particularly immunosuppressive, including many secreted
and cell-based immune suppressive mecha nisms. 1 Progra mmed
death ligand-1 (PD-L1) is a labile,
inducible transmembrane receptor
ligand that facilitates immune system
evasion through co-ligation of its
receptor, PD-1, on activated T-cells.2
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Figure: Kaplan–Meier survival estimates comparing high and low PD-L1 expression
in glioblastoma (A) Differences in survival curves from tumors meeting the 2007 WHO
histologic criteria for glioblastoma (5% PD-L1 cut-off) (B) Differences in survival curves from
recurrent IDH-wildtype glioblastoma reclassifed according to the 2016 WHO nomenclature
(5% PD-L1 cut-off) (C) TCGA survival curves, classifed only as glioblastoma, stratifed by
median PD-L1 mRNA expression (D) Survival curves from TCGA patients after fltering for
recurrent, non–G-CIMP (IDH-wildtype) tumors (median PD-L1 mRNA cut-off)
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Upregulation of PD-L1 on tumor cells
has been proposed as a mechanism of
immune escape in gliomas,3 and its
detection at the protein level has been
previously demonstrated.4,5 However,
study characteristics (grading, sample
size) and technical considerations
(assays, cut-offs) have resulted in
highly variable rates of expression —
ranging from 6.1% to 88% in larger
studies. 4 Furthermore, the role of
PD-L1 as a prognostic marker in
gliomas, independent of predicting
treatment response, remains contentious. A specific cut-off for PD-L1
expression has not been established
in glioblastoma, and it remains to
be seen what role PD-L1 expression
has in patient selection in future
clinical trials which include PD-1/
PD-L1 blockade — as either a predictive or prognostic marker. Here, we
sought to address the prognostic role
of PD-L1 in recurrent glioblastoma
in a large tumor cohort according
to the updated 2016 World Health
Organization (WHO) classifcation
of difuse gliomas. Additionally, we
sought to localize cellular expression
of PD-L1 in the tumor microenvironment using multiplex immunofuorescence in post-treatment glioblastoma.
Checkpoint inhibition has demonstrated clinical efcacy in a variety
of solid tumors. Reports of PD-L1
expression in glioblastoma are highly
variable (ranging from 6% to 88%)
and its role as a prognostic marker has
yielded conficting results. To validate
the prevalence and prognostic role of
PD-L1 expression in a large cohort of
difuse gliomas according to the 2016
revised WHO classifcation. Using
tissue microarrays, we compared 5
PD-L1 monoclonal antibodies (n = 56)
and validated expression (n = 183) using
quantitative immunohistochemistry
(IHC) and RNA in situ hybridization (RISH). Expression data from
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PD-L1 IHC (SP263) N(%)
Total
n = 183a

≥1% n = 54 ≥5% n = 43 ≥25% n = 28
(29 5)
(23 4)
(15 3)

Age (yr)
Median (range)

48 (4-75)

52 (4-74)

53 (18-74)

53 (23-74)

Female

57 (31)

16 (30)

14 (33)

6 (21)

Male

124 (69)

38 (70)

29 (67)

22 (79)

Primaryb

46 (25)

13 (24)

11 (26)

9 (3)

Recurrent/posttherapy

137 (75)

41 (76)

32 (74)

19 (68)

Sex

Presentation

Diagnosis (WHO 2016)
LGG

6 (3 3)

0 (0)

0 (0)

0 (0)

21 (11 6)

1 (1 8)

0 (0)

0 (0)

AO, IDH-mut/1p19q
codeleted

5 (2 7)

2 (3 7)

1 (2 3)

1 (3 6)

Glioblastoma, IDHwt

81 (44 2)

37 (68 5)

30 (69 7)

20 (71 4)

Glioblastoma, IDHmut

13 (7 1)

2 (3 7)

1 (2 3)

0 (0)

Glioblastoma, NOS

31 (16 9)

12 (22 2)

11 (25 6)

7 (25)

DMG, H3K27Mmut

16 (8 8)

0 (0)

0 (0)

0 (0)

AA, IDHmut

TABLE:
LGG, low-grade (diffuse) glioma (WHO grade II); AA, anaplastic astrocytoma; AO,
anaplastic oligodendroglioma; DMG, diffuse midline glioma
an = 5 cases did not have available clinical information
bPrior to chemotherapy or radiotherapy
Glioblastoma, NOS: WHO grade IV diffuse gliomas with negative IDH R132H staining
and an alternative IDH1 or IDH2 mutation probability between 11 and 89%
Not shown: AANOS (not otherwise specifed, n = 2); AAIDHwt (n = 1); AOANOS
(anaplastic oligoastrocytoma, n = 1); AONOS (n = 1); DMG non-H3K27M (n = 5)

The Cancer Genome Atlas (TCGA)
and published studies were compared
with clinical outcome. Multiplexed
immunophenotyping was used to
identify PD-L1+ cell populations in
post-treatment glioblastoma. Using
a 5% cut-of, PD-L1 expression was
signifcantly associated with a poor
prognosis in both histologically
defned (n = 125, log-rank P < .001) and
recurrent isocitrate dehydrogenase
(IDH)-wildtype glioblastoma (n = 60,

log-rank P = .015). PD-L1 remained a
signifcant negative prognosticator in
Cox regression analysis (hazard ratio:
1.96, P = .021). Analysis of TCGA data
confrmed decreased overall survival
in recurrent non–glioma CpG island
methylator phenotype (G-CIMP)
glioblastoma (n = 12, log-rank P = .023),
but not in glioblastoma as a group (n =
444, log-rank P = .135). PD-L1 RISH
Continued on p. 18
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showed a signifcant correlation with
IHC (P < .0001). PD-L1 was observed
in the proliferating perivascular
stem cell and immune niche of posttreatment glioblastoma. A 5% PD-L1
expression cut-of identifed a subset
of glioblastoma that is associated with
a worse clinical outcome. This association remained signifcant within
the newly defned IDH-wildtype classifcation. These fndings could have
implications for patient stratifcation

in future clinical trials of PD-1/PD-L1
blockade.
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Hidradenitis suppurativa (HS) is
a chronic inflammatory disease of
the skin which classically presents
as recurrent painful and exudative
lesions most often found in intertriginous areas with high densities
of apocrine glands. HS prevalence
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is estimated between 0.05% and
4.10% of the population; however, its
morbidity can be signifcant due to
the debilitating nature of the lesions
and the social stigma associated with
purulent and malodorous discharge.1
While the exact pathophysiology of
HS is not known, the NOTCH signaling pathway involved in embryologic development, cell diferentiation,
and molecular signaling has previously
been implicated without identifcation
of exact genes.2,3 This study aims to
evaluate the cytoarchitecture, cell surface markers, and molecular signaling
pathways present in HS patients to
further understand the disease and
identify potential therapeutic targets
to ultimately provide an alternative to
surgical excision.
Samples were obtained from 11
patients with HS who underwent
surgica l excision and compared
to 11 samples of normal skin (NS).
Histopathology of HS and NS samples
were compared via hematoxylin and
eosin (H&E) staining and imaging at
10x magnifcation.

Anti-CD3, a T-cell marker, and
anti-CD31, a PECAM and vascular
T-cell specifc marker, were used for
immunohistochemical (IHC) analysis.
IHC was conducted in four HS and
four healthy skin specimens with six
regions of interest (three epidermal
and three dermal) per sample. Cellular
quantifcation was performed at 40x
magnification and compared with
Student’s t-test.
Finally, RNA was extracted and
quantifed, and cDNA was generated
via reverse transcriptase PCR from
3 NS and 4 HS biopsies. A NOTCH
signaling PCR array was used to
identify the degree of gene regulation.
Candidate genes were identified if
their fold change was greater than or
less than 2.5 when compared to normal
skin in at least three of the HS samples.
Histopathologic examination
showed that HS skin had wider epidermal layers, extending into and
engulfng the dermis, as well as extensive dermal cellular infltration and
aggregation. IHC analysis revealed
that, at the dermal level, HS lesions
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had a signifcantly greater quantity of
CD3+ (324.29±139.28 vs. 14.93±16.32,
p<0.0001), and CD31+ (322.15±155.46
vs. 2.84±5.56, p<0.0001) cells/mm2
than healthy skin samples (Table).
NOTCH array analysis identifed three genes in HS with a 2.5-fold
upregulation compared to NS: KRT1
(keratin family), UbD (ubiquitin
D), and CCNE1 (cyclin-dependent
kinase). Ten genes were down-regulated in HS more than 2.5-fold compared to NS: CCND1 (cyclin D1
regulator of G1/S transition), Hey1
(involved in somite development),
MFNG (demarcates boundaries
during embryological development),
MMP7 (metalloproteinase involved
in tissue remodeling), Notch 4 (cell
proliferation and differentiation),
DLL4 (encodes for NOTCH ligand),
LFNG (defines boundaries during
embryological development), PPAR-g
(adipocyte diferentiation), and LMO2
(yolk sac erythropoiesis).
Epidermal and dermal cytoarchitecture of HS lesions difer in comparison to healthy skin with HS lesions
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Immunohistochemical Identifcation and Quantifcation of
Cells in Hidradenitis Suppurativa vs. Normal Skin
Skin Type

CD3

CD31

Epidermis
(n=12)

Dermis (n=12)

“Hidradenitis
Suppurativa
(cells/mm2±SD)”

2 28±5 46

324 29±139 28 4 27±7 72

“Normal
(cells/mm2±SD)”

6 40±10 37 14 93±16 32

2 84±4 20

2 84±5 56

p-Value

0 2123

0 5806

<0 0001

<0 0001

Epidermis
(n=12)

Dermis (n=12)
322 15±155 46

TABLE:
demonstrating a signifcantly greater
dermal lymphocytic infltrate compared to healthy skin. Additionally,
genes involved in embryological development as well as skin and adipocyte
differentiation are dysregulated in
HS. Work is ongoing to correlate the
identifed candidate genes with their
respective protein levels by IHC with
the goal of identifying molecular targets for treatment of HS.
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Cancers exhibit altered DNA methylation compared to normal cells,
including decreased methylation at
regions normally silenced for genome
stability and increased methylation
at promoter regions of tumor suppressors. 5-azacytidine (Aza) is a
DNA methyltransferase inhibitor
(DNMTi) that removes DNA methylation and is FDA approved for the
treatment of myelodysplastic syndrome. We have shown that DNMTi
upregulate the interferon response,
tumor antigens, and antigen presentation in solid tumors, contributing to
an overall upregulation in immune signaling.1 DNMTi activate a canonical
interferon signaling pathway through
upregulated expression of dsRNA,
specifcally hypermethylated endogenous retroviruses (ERVs) that activate dsRNA sensors. The interferon
response activated by ERV signaling
recruits immune cells, promoting
tumor clearance and sensitization to
immune therapy.2
We sought to determine whether
DNMTis cause a similar ERV activation and cell killing in B - and
T-cell malignancies, focusing frst on
mantle cell lymphoma (MCL). We
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FIGURE 1: Dose response curve for AZA treatment

further hypothesized that mutations
in ten-eleven translocation methylcytosine dioxygenases (TET), enzymes
that normally demethylate DNA,
might lead to a hypermethylated
state making cells more resistant to
direct cytotoxicity from DNMTis.
We also sought to test the efects of
TET mutation on ERV induction
and immunogenicity. For 5-Aza to
inactivate DNMTis it must be incorporated into the DNA of actively

dividing cells. Since Aza is only stable
in the body for <30 minutes and MCL
cells have slow doubling times, only a
fraction of cells divide during that 30
minute window. To improve response
in these cancers, extended drug availability is necessary.
We used three different treatment regimens to demonstrate that
extending the availability of active
drug shows a better response, significantly more so than increasing
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Relative expression normalization to control

the drug dose or treating for a longer
period of time. The treatments
included: one dose a day for 3 days (3
Day Tx; blue), one dose a day for 5 days
(5 Day Tx; red), and three doses a day
for three days (3X3 Tx; green). This
was done for a dose response curve
of 250, 500, 1000, 2000, and 4000
ηg/mL, compared to PBS control (0).
Figure 1 shows the percentage of live
cells at two time points, day 6 and 9
after starting treatment. In the TET
wild type MCL cells (Maver, Mino,
Jeko) the 3X3 group showed better
killing when compared to 3- and
5-day Tx. The differences between
the 3X3 treatment and the single
dose per day was more pronounced in
the slowest growing cell lines. Mino,
which showed the largest diference
in killing, doubles between 50-72hrs,
whereas Jeko (doubling time 26-33hrs)
shows a less drastic diference between
the 3 dose versus 1 dose per day groups.
This supports the hypothesis that
slower growing tumors beneft from
sustained drug delivery over increased
drug dose. TET mutated leukemia
cells (Karpas299, CCRF-CEM), were
less Aza sensitive. This supports our
hypothesis that TET mutations lead
to a hypermethylated state more
resistant to DNMTi. The resistance
correlates with the extent of TET
mutations. Karpas, the most resistant, has mutations in TET1 and
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TET2, whereas CCRF only has TET3
mutated. In vivo responses by these
tumors to DNMTi is likely due to
increased immunogenicity, rather
than just direct cytotoxicity, which
is supported by the increase in ERV
expression shown in Figure 2 (ERVs
profiled: Syncytin-1, ervFC2, and
envW2). CCRF showed increased
ERV expression in both the fve-day
treatment and the 3X3 treatment.
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The brain uses glucose and related
substrates for energy (Berg et al., 2002)
but how the brain transports and uses
glucose during development has not
been completely characterized. The
aim of this project is to compile an
age, region- and cell-specifc profle
of glucose transport and utilization
during development using a mouse
model. This profile can be used to
better understand metabolic changes
in pediatric diseases such as perinatal
hypoxia, epilepsy, hyperglycemia, and
mitochondrial disease.
Brains of C57Bl/6 mice were
har vested and dissected at ages
P11, P15, and P30, corresponding
to neonates, young children, and
adolescents respectively. The frontal
cortex, hippocampus, and white
matter were isolated by microdissection, each having diferent cell
populations important in learning,
memory, and cognition during early
development. Glucose transporters
(GLUT) 1, 2, 3, 4, and 8 were selected
as measures of brain glucose transport
(Gomez et al., 2010) and quantifed via
Western Blotting.
GLUT1 is in the blood-brain barrier endothelium (Sankar et al., 2002).
As vascularization is established early,
we did not expect signifcant changes
in GLUT1 expression during development, and no signifcant diference
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FIGURE 1: Western Blot of GLUT2 levels in the frontal cortex (FC), hippocampus
(H), and white matter (WM) of P11, P15, and P30 mouse brains (top) Western
Blot quantifcation of GLUT2 levels, expressed as ratio to actin in the frontal cortex,
hippocampus, and white matter of P11, P15, and P30 mouse brains (N = 3) (bottom)

between ages in the frontal cortex was
seen (Figure 1).
GLUT2 is preferentially expressed
in astrocytes (Qutub and Hunt, 2005).
As the number of astrocytes increases
with age (Reemst et al., 2016), we
expected an increase in GLUT2
expression during development, especially in the hippocampus (Oberheim
et al., 2012). GLUT2 expression was
signifcantly increased by P30 in the
frontal cortex and (Figure 2) and
there was no signifcant diference in
GLUT2 expression in white matter.
GLUT3 is the main glucose transporter in neurons (Gomez et al.,
2010), but there is little temporal and
no region-specific data for GLUT3
expression. Results showed no statistically signifcant changes in GLUT3
expression in the hippocampus and
white matter and a mild statistically
insignificant upward trend in the
frontal cortex. The lack of statistical
significance may be that the peak
expression occurs between the ages

we analyzed and was not detected.
GLUT4 and GLUT8 are both
insulin-dependent glucose transporters (Sankar et al., 2002). An
upward trend in GLUT4 expression
by P30 was seen, but no signifcance
in the frontal cortex, hippocampus, or
white matter was seen. There was very
high variability among individuals.
GLUT 8 expression, however, showed
an extremely signifcant increase in
P30 mice in the frontal cortex, hippocampus, and white matter, which
can be explained by the feeding pattern of mice. From birth until P15,
the mice are in their suckling phase
and receive mostly proteins and fatty
acids through their mothers’ milk
(McKenna et al., 2015) but by P30
mice feed on their own and have a
diet rich in carbohydrates, which
stimulates insulin release. Since
GLUT8 is an insulin-dependent
glucose transporter, the increase in
insulin should cause an increase in
expression of GLUT8 in the brain.
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Although GLUT4 should have shown
similar patterns in expression, it is
only weakly expressed in the brain.
Therefore, GLUT8 may be the key
insulin-dependent glucose transporter in the brain. Links to metabolic
changes in diabetic pediatric patients
should be further explored.
Future studies include immunostaining human brain from a neonate,
a young child, and an adolescent. Mice
subjected to perinatal hypoxia will
be compared to this profle to better
understand the metabolic changes
that occur in this common pediatric
form of brain injury.
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FIGURE 2: Western Blot of GLUT8 levels in the frontal cortex (FC), hippocampus
(H), and white matter (WM) of P11, P15, and P30 mouse brains (top) Western
Blot quantifcation of GLUT8 levels, expressed as ratio to actin in the frontal cortex,
hippocampus, and white matter of P11, P15, and P30 mouse brains (N = 3) (bottom)
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Osteoporosis is a signifcant burden
for our aging population. Developing
a better understanding of the genetic
underpinnings of poor bone quality
may assist in the future development
of prevention strategies. A study by
Correa-Rodriguez (2016) identifed a
group of single nucleotide polymorphisms (SNPs) that were associated
with both body composition and bone
mineral density (BMD) in a population of Caucasian young adults.1 In
particular, they found rs3736228 in
the low-density lipoprotein receptor
related protein 5 (LRP5) gene particularly inf luenced BMD. SNP
rs3736228 has been demonstrated to
have a pleiotropic efect on phenotypes, demonstrating associations
in other studies with body composition, circulating nutrient levels, and
obesity. 2,3,4 The aim of this study
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Characteristic

Females

Males

N

Mean ± SD

N

Mean ± SD

Age (years)

96

22 3 ± 4 4

93

23 7 ± 4 2

Weight (kg)

96

62 4 ± 9 2

93

78 0 ± 12 3

Height (cm)

96

165 9 ± 5 8

93

178 8 ± 7 7

BMI

96

22 7 ± 2 9

93

24 3 ± 3 1

TABLE: AIMMY Demographics
is to expand existing knowledge of
LRP5 and explore the association of
rs3736228 polymorphisms and BMD
to replicate the fndings of previous
studies regarding the association of
SNP rs3736228 with BMD in a cohort
of healthy young adults.
Participants from the University
of Calgary cohort from the Assessing
In herited Metabol ic Sy nd rome
Markers in the Young (UC AIMMY)
study included 209 healthy young
adults and mixed ethnicity, predominantly Caucasian (81%) young
adults (male n=102, female n =107,
average age=23 years). Phenotypes
were height, weight, body mass index
(BMI), and total BMD. Genotyping:
Allelic discrimination was determined using Applied Biosystems
Taqman and Applied Biosystems
7900HT Realtime PCR. Statistical
Analysis, after being tested for HardyWeinberg equilibrium (HWE), the
data was stratified by sex and analyzed using analysis of covariance
(ANCOVA) and a dominant model.
Where the f-tests were signifcant,
post hoc pairwise comparisons were
performed and the resulting p-values
were adjusted for multiple comparison
using the Sidak method.
The genotype distribution for

rs3736228 in the AIMMY cohort was
found to be in HWE. Using a dominant model, we found that females
with one or more copies of the risk
T allele had a signifcant lower mean
total BMD (CC: n=69, 1.129 ± 0.010;
CT/TT n=29, 1.089 ± 0.016; p = 0.0347).
However, a similar association was
not seen in males. No signifcant associations were observed with height,
weight, or BMI.
The rs3736228 polymorphism
within the LRP5 gene was found to
be negatively associated with BMD
in females in the UC AIMMY cohort.
It is known that the polymorphism
rs3736228 alters the codon in position 1330. The more common C allele
encodes alanine, while the minor T
allele encodes valine. This mutation
downregulates the LRP5 cell surface
receptor function, which plays a
pivotal role in bone formation. The
LRP5 gene has now been shown in
multiple studies to be associated with
bone quality measures like calcaneal
Quantitative Ultrasound (QUS) and
BMD. Our study has expanded these
fndings and suggests that rs3736228
also infuences BMD in healthy young
females. This supports the work
of a recent study which found that
when stratifying by sex, females only
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showed a trend towards signifcance
in calcaneal QUS measures.1 While
the development of BMD is polygenic,
our work suggests that focus on LRP5
polymorphisms may be particularly
helpful in defining genetic risk for
low BMD. In addition, given that
this polymorphism has shown to have
pleiotropic efects, we plan to investigate the associations of rs3736228 with
other anthropomorphic phenotypes.

Total Bone Mineral Density in Males
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Previous studies have identified
specifc genetic loci associated with
variation in bone mineral density
(BMD) in genome-wide association
analyses.1,2 One region in chromosome
2p22-25 was found to have signifcant
association with BMD variations in
the lumbar spine.3 Growth Regulation
by Estrogen in Breast Cancer 1 gene
(GREB1), a gene within this loci, was
recently shown to be upregulated
during osteoblast and chondroblast
diferentiation.4 In one study, genetic
variants of GREB1 were found to be
associated with BMD variations at
the lumbar spine and femoral neck
in Caucasian adults, establishing
GREB1 as a target gene for future
BMD genetic studies.5 The current
study sought to elucidate the role of

genetic variation in GREB1, specifcally polymorphisms rs5020877 and
rs10929757, on BMD measures in a
cohort of African American children
as well as two cohorts of Caucasian
young adults.
The relationship between GREB1
polymorphisms and phenotype were
assessed in three distinct cohorts: Bone
Health, 73 healthy African American
children previously recruited to assess
fracture risk factors; Functional
Single Nucleotide Polymorphism
Associated with Human Muscle
Size and Strength (FAMuSS), 368
hea lthy Caucasian young adults
previously recruited as part of a
3-month long program to evaluate
Continued on p. 26
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genetic infuences on strengthening
muscles in the non-dominant arm;
and Assessing Inherited Markers of
Metabolic Syndrome in the Young
(AIMMY ), 153 health Caucasian
young adults and 75 healthy African
American young adults previously
recruited to identify signifcant risk
factors for metabolic syndrome.
The Applied Biosystems Taqman
Allelic Discrimination Assays and
Real-Time PCR system were used
to genotype the DNA samples from
the cohorts. All statistical analyses
were performed separately by gender,
and Hardy-Weinberg Equilibrium
(HWE) was assessed for each SNP
in race-specifc cohorts. Analysis of
covariance (ANCOVA) tests were
utilized, where the respective covariates were entered into the model.
Post hoc pair-wise comparisons were
performed, and the resulting p-values
adjusted for multiple comparisons
using the Sidak method.
Both SNPs were found to be in
HWE in the FAMuSS and AIMMY
cohorts, but neither was in HWE
in the Bone-Health cohort. In the
Bone Health cohort, rs5020877 was
significantly correlated with Dual
X-Ray Absorptiometr y ( DEX A)
bone mineral content (BMC) in the
lumbar spine in males (p=0.036) as
well as left hip (p=0.036); whereas,
in females, rs10929757 was significantly associated with total body
BMD (p=0.016), as well as BMD for
the left hip (p<0.001), lumbar spine
(p=0.036), and total body (p=0.035).
In the FAMuSS cohort, rs5020877
genotype was significantly associated with baseline one-rep maximum
(1-RM) strength in the non-dominant
(ND) arms of females (p=0.021). In
the AIMMY cohort, neither SNP
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Covariates
used
Baseline isometric strength —
Non-dominant arm

Age, weight

Baseline isometric strength —
Dominant arm

Age, weight

Baseline 1-RM strength —
Non-dominant arm

Age, weight

Baseline 1-RM strength —
Dominant arm

Age, weight

Baseline bone (+ marrow)
volume — Dominant arm

Age, weight

Baseline bone (+ marrow)
volume — Non-dominant arm

Age, weight

Baseline cortical bone volume
— Dominant arm

Age, weight

Baseline cortical bone volume
— Non-dominant arm

Age, weight

Sex

rs5020877

rs10929757

F

0 14

0 13

M

0 35

0 41

F

0 15

03

M

0 32

0 33

F

0 021

0 43

M

0 19

0 61

F

0 11

0 48

M

0 29

0 42

F

0 32

0 48

M

0 66

07

F

0 11

0 44

M

0 71

0 87

F

0 44

0 26

M

0 61

0 94

F

0 051

0 33

M

0 69

0 53

TABLE: Phenotype Analysis for GREB1 Polymorphisms in the FAMuSS Cohort
showed a signifcant association with
any phenotype. There were no signifcant SNP-SNP interactions between
rs5020877 and rs10929757 for any of
the phenotypes analyzed.
The results from this study demonstrate that variations in the GREB1
gene, originally known for its role in
tumor progression and more recently
for its role in osteoblast/chondroblast
diferentiation, may contribute to differences in baseline 1-RM strength of
dominant and non-dominant arms,
lumbar spine BMC as well as total
body, left hip, and lumbar spine BMD.
These fndings suggest independent
effects of these two loci and that
patients with rare allele for rs5020877
are stronger but have decreased bone
quality while those with the rare allele
for rs10929757 have an increased bone
quality. However, given the small
number of patients having the rare
allele for either SNP, further study is
needed to verify these fndings.
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There is a pronounced onco-racial
disparity in Washington, D.C., which
had the highest national incidence of
breast cancer in African American
patients between 2010 and 2015 and
the worst outcomes. 1 Recent data
indicates a higher incidence of deleterious BRCA1 [and BRCA2] mutations
and variants of uncertain signifcance
(VUS) in African American patients
compared to Caucasian patients when
controlling for patients of Ashkenazi
Jewish (AJ) descent. 2 Despite this,
African American women meeting
National Comprehensive Cancer
Network (NCCN) criteria for genetic
testing are less likely to complete
such testing compared to Caucasian
women nationally. 3 Studies have
investigated psycho-social drivers of
minority patient aversion to genetic
testing. We hypothesize that lack of
physician referral for cancer genetic
counseling and testing for African
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FIGURE 1: Physician referral rates for breast cancer patients treated at GW Cancer
Center between 2014 and 2018 meeting NCCN criteria differed signifcantly by race
(BNH 76 5%, N = 88 and WNH 92 7%, N=127; χ2=13 0642, p-value=0 00030
(p-value signifcance <0 05)
American women contributes to this
disparity.
A total of 1,180 patients (nonHispanic African Americans (BNH)
N=502; non-Hispanic whites (WNH)
N=435) were treated at the George
Washington Cancer Center (GW
Cancer Center) for breast cancer
(both in situ and invasive carcinoma),
between 2014 and 2018. Utilizing GW
Cancer Center’s Cancer Registry, we
identifed women by race (BNH N
=115; WNH N =137) who met select
NCCN criteria for referral for genetic
evaluation including breast cancer
diagnosis under age 50, triple negative breast cancer (TNBC) under age
60, and two primary breast cancers.
Excluded patients were those who
were not BNH or WNH or who did
not meet the select NCCN criteria
listed above. Patients were then
stratifed by race according to who
underwent genetic evaluation (BNH

N= 81, WNH N= 116), whether at
our Ruth Paul Cancer Genetics and
Prevention Service (RPCGPS) or
elsewhere, by reviewing GW Cancer
Center records, RPCGPS records,
and patient clinic records for genetic
screening results from outside institutions. Patient charts were used to
identify individuals who received a
physician referral during the course
of their cancer care.
Twenty-one percent of breast
cancer patients seen in GW Cancer
Center between 2014–18 met study
criteria for referral for genetic evaluation (n = 252; BNH N=115, WNH
N=137), including breast cancer diagnosis under age 50 (BNH N = 76;
WNH N = 108), TNBC under age
60 (BNH N =14; WNH N =5), and
two primary breast cancers (BNH N
= 18, WNH N = 16). Several patients
Continued on p. 28
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identifed met two or more criteria
for referral (BNH N = 7, WNH N =
8). Physician referral rates differed
significantly by race (BNH 76.5%,
N = 88 and WNH 92.7%; N= 127; χ2
=13.0642, p-value=0.00030) (Figure
1). There was no significant difference in adherence by race for patients
referred to genetic counseling (BNH
92%, N=83; WNH= 91%, N=123, χ2
=0.00178, p-value=0.894) (Figure 2).
Low genetic testing rates for
African American breast cancer
patients a re a n i mped iment to
resolving the prominent onco-racial
breast cancer disparities, particularly
in young, TNBC, and patients with
multiple primary tumors. This study
identifed a race-based phenomenon
in physician referral rates. Possible
reasons for this discrepancy may
include lag in physician education on
the topic of hereditary risk, barriers
in physician-patient communication
and/or implicit bias. Future work
is needed to clarify the root cause

28

Not
Evaluated

-~32

14

83

Evaluated

0

20

40

60

80

-

100

123
120

140

Numer of Individuals
■ non-Hispanic African Americans
■ non-Hispanic Caucasians

FIGURE 2: Individual patients treated for breast cancer at GW Cancer Center between
2014 and 2018 who met NCCN criteria for referral and were referred by their physician
for genetic counseling stratifed by race and referral adherence
in order to increase the identification of at-risk women in the African
American community.
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We sought to determine the utilization of otolaryngology and speechlanguage pathology services among
infants following open cardiothoracic
procedures. Given their susceptibility
to iatrogenic-induced vocal cord
dysfunction, the proper use of ancillary services is critical in limiting

long-term swallowing and speech
complications.
A fourteen-month retrospective
review of the Society of Thoracic
Surgeons database at a single tertiary
children’s hospital was performed to
include all infants undergoing open
cardiothoracic surgery. Demographic,
operative, and outcome variables were
identifed.
Our results showed, 67 patients
were identifed (36M/31F; mean [SD]
gestational age 36.5 [4.5] weeks) whose
surgeries included patent ductus
arteriosus ligation (n=20), aortic
operation (n=10), Tetralogy of Fallot
repair (n=8), and Norwood procedure (n=6). Post-operatively, 20/67
patients (30%) had documented weak
cry or weak cough; of these, 10 were
evaluated by otolaryngology, and
seven were found to have vocal cord
paralysis. 30/67 patients (45%) had

post-operative feeding difficulties,
and 13 had documented aspiration.
Of the 13 with aspiration, fve underwent a modifed barium swallow with
speech-language pathology, and fve
had otolaryngology consultations.
On discharge, 13/67 patients (19%)
necessitated gastrostomy tube placement, and 8/67 patients (12%) required
supplemental oxygen or continued
ventilation. Following discharge, 8/67
patients (12%) were followed by otolaryngology for vocal cord paralysis
(n=7), persistent dysphagia (n=3), or
stridor (n=2).
Open cardiothoracic surgery in
infancy is associated with high rates
of voice and swallowing dysfunction.
Inpatient ancillary services are underutilized in managing this population,
and outpatient follow-up is poor,
suggesting the need for prospective
protocols to ensure adequate care.
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The anterior cruciate ligament (ACL)
is one of the most commonly injured
knee ligaments which requires extensive rehabilitation. Athletes who
injure their ACL risk long-term
disability compromising general
function, including increased rates
of osteoarthritis. Roughly 80% of
ACL injuries have a noncontact
origin, suggesting that ACL injury
risk is greatly infuenced by patterns
of motion.1 The potential beneft of
prospectively identifying diferences
in landing strategies has prompted

the development of ACL injur yprevention programs utilizing biomechanical interventions, which correct
hazardous movement abnormalities
and reduce rates of injury.2 Studies
have identifed specifc movements,
such as excessive internal rotation
angles at the hip and knee, as placing
individuals at greater risks for ACL
injury. To detect these abnormalities, motion capture technologies are
Continued on p. 30
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employed, but they are often expensive, labor-intensive, and impractical
screening tools in clinic.3 The depth
camera in the Microsoft Kinect 2
system has emerged to be a promising
low-cost assessment system that utilizes surface mapping technology to
generate high-quality human kinematic profiles. It maps surfaces by
sending out bursts of infrared light,
which provide real-time tracking
of human limbs. 4 This study seeks
to evaluate knee kinematics in the
controls, ipsilateral, and contralateral
leg of ACL reconstructed patients to
assess ACL injury risk.
A cross-sectional study of ACL
reconstructed patients at 6 months
post-operation (n=15) and controls
(n=12) was performed. Participants
performed three single leg squats for
each leg with arms spread out and
opposite leg forward, with movement captured via the Microsoft
Kinect 2 camera placed 1-2 meters
in front of the participant. Custom
MATLAB software was utilized to
analyze raw data, which included hip
internal rotation (IR), adduction, and
knee fexion at the highest point of
flexion. Negative values for hip IR
corresponded to hip external rotation. Statistics comparing control,
contralateral, and ipsilateral legs were
conducted using one-way analysis
of variance and student T-test, with
signifcance set at p < 0.05.
The mean age in years was 27.7 and
31.2 for the control and ACL reconstructed groups, respectively. The percentage of females was 17% and 51%
for control and ACL reconstructed
groups, respectively. For degree of hip
IR, the contralateral group (7.74) was
signifcantly higher than those of the
ipsilateral (-2.06; p<0.05) and control
group (-1.94; p<0.05). There was no

30

120

10

*

100

8

*

6

80

85 5

60
40

*

55 4

4
2

64 7

0

20

-2

0

-4
Reconstructed Control Contralateral

Hip IR

■ Reconstructed
■ Control

FIGURE 1: Bar graph comparing
knee fexion across all groups
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FIGURE 2: Bar graph comparing
signifcant diference in hip adduction among all groups. Comparing
knee fexion, controls (85.5) had signifcantly higher degrees of fexion
compared to reconstructed (55.4;
p<0.01) knees.
At the greatest point of fexion,
the contralateral leg in the ACL group
demonstrated significantly more
internal rotation during a single leg
squat, thereby indicating that the
knee control in the contralateral
leg is abnormal. Rehabilitation may
have improved deficiencies in the
reconstructed knee while abnormal
mechanics on the contralateral side
may further predispose patients to
injury on that side. While not signifcant, ipsilateral knees had higher hip
adduction than that of contralateral
and control knees. This could also
be used as a motion analysis marker
for abnormal reinjury biomechanics.
The depth camera accurately quantifed that ACL patients cannot reach
the same knee fexion as controls in
both the ipsilateral and contralateral
leg; instead, ACL patients performed
abnormal compensatory behaviors
that further increased risk of reinjury. Therefore, this preventionfocused motion analysis system has
emerged as a fast, low-cost, and
non-invasive method to assess lower

hip IR, hip abduction across all
groups Negative values for hip IR
correspond to external rotation
extremity biomechanics with great
research and clinical utility.
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While extensive research has assessed
treatment outcomes in muscle invasive
bladder cancer, lymph node positive
disease (LN+) has been excluded from
randomized studies or grouped with
metastatic disease.1-3 Although node
positivity confers reduced 5-year
cancer specifc and overall survival, it
is potentially curable if treated before
systemic metastasis. 4 Treatment is
not standardized, however, especially
with lack of radiographic response
to induction chemotherapy.5 This
study seeks to compare outcomes and
demonstrate trends in treatment for
LN+ bladder cancer.
We performed a retrospective
cohort study using the National
Cancer Database (2006-2014) and
identifed 1869 cT2-4N1-3M0 bladder
cancer patients treated with (1) radical
cystectomy (RC), (2) neoadjuvant chemotherapy (NAC) + RC, (3) adjuvant
chemotherapy (AC) + RC, (4) radiation
+ chemotherapy, (5) chemotherapy
alone, or (6) no treatment/palliative
care only. The primary outcome was
survival by treatment, analyzed using
Kaplan-Meier and multivariable
Cox-proportional hazards regression.
Secondary outcomes included pathologic down-staging, analyzed using
univariable/multivariable logistic
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regression models. A univariable
logistic regression model of treatment
by year was used to identify treatment trends over time. Multivariable
models were adjusted for confounding
demographic, facility-level, and clinicopathologic variables.
Among 1869 patients (cN1, 48%;
cN2, 44%; cN3 8%), 567 underwent
RC , 4 18 u nder went NAC , 591
u nd er w ent AC , 61 u nd er w ent
rad iat ion + chemot herapy, 13 6
under went chemotherapy alone,
and 96 had no defnitive treatment.
Overall survival did not difer between
NAC and AC, but both had improved
survival compared to RC alone. All
other treatment groups had worse
survival outcomes in comparison to
NAC. When comparing NAC to RC
alone, down-staging to pT0 (adjusted
odds ratio [aOR]=26.39) and pN0

(aOR=6.88) was higher for NAC.
Overall, utilization of NAC and no
treatment has increased, use of AC
and RC alone has declined, and use of
chemotherapy and radiation without
surgery has not changed signifcantly.
Combined chemotherapy and RC
is associated with improved outcomes
for LN+ bladder cancer compared to
RC or chemotherapy alone, although
there is no significant difference
between NAC and AC. Use of radiation and chemotherapy without RC
has stayed consistent and is associated with worse oncologic outcomes
compared to RC with perioperative
chemotherapy, but there is no signifcant diference when compared to RC
or chemotherapy alone.
Continued on p. 32
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With well over a million procedures
performed annually, 1 arthroscopy
of the knee and shoulder are two
of the most commonly performed
orthopaedic surgeries. Optimization
of patient outcomes by minimizing
modifable risk factors is crucial, and
one well-established modifable risk
factor is smoking. Approximately
15.5% of Americans smoke,2 and the
prevalence of smoking is highest in
males ages 25-64,3 a group which also
encompasses the majority of patients
undergoing arthroscopic procedures.1
The frst step towards mitigating
the risk associated with smoking is to
defne its impact on postoperative outcomes. The purpose of this study was
to evaluate any association between
preoperative smoking and perioperative and early postoperative complications in a large population following
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Procedure

aOR for smokers
vs non-smokers

Lower 95% CI

Upper 95% CI

p

KAM

1 228

0 979

1 541

0 08

SHADEC

1 462

1 03

2 075

0 033

KAC

1 058

0 703

1 592

0 79

KAA

1 213

0 859

1 713

0 27

KAB

1 969

1 407

2 757

< 0001

DCSA

1 137

0 686

1 883

0 62

SHADEB

1 933

1 211

3 084

0 006

SHACUR

1 297

0 874

1 925

02

aOR: adjusted odds ratio; CI: confdence interval. KAM: Knee arthroscopy with
meniscectomy (medial or lateral); SHADEC: shoulder arthroscopy with decompression;
KAC: knee arthroscopy

TABLE: Adjusted odds of reaching the composite outcome* for smokers, by
procedure
*Composite outcome: Any cardiac, renal, wound (including all surgical site infections),
sepsis, thromboembolic, or pulmonary complication as recorded in the NSQIP database.
shoulder and knee arthroscopic surgery for sports injury.
The National Surgical Quality
Improvement Program (NSQIP)
database was queried retrospectively
for patients who underwent knee or
shoulder arthroscopic surgery for
sports injury between 2010-2016.
These patients were identifed using
the current procedural terminology
(CPT) codes. This database provides

an invaluable source of data on a
large sample of patients collected in a
reliable, systematic way from centers
across the country.
Deaths a nd compl ications
recorded in the frst 30 days postoperatively were included and categorized
as cardiac, renal, wound (including
all surgical site infections), sepsis,
thromboembolic, or pulmonary. A
composite outcome was formed and
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defned as positive if a patient experienced any of the above complications.
Univariate and multivariate analyses
were performed to determine whether
preoperative smoking was an independent risk factor for any of these postoperative complications individually
or for the composite outcome.
The study included 134,822 cases.
In univariate analysis, smoking was
associated with increased rates of complication in knee arthroscopy with
the following: ACL reconstruction
or medial and lateral meniscectomy,
and shoulder arthroscopy with the
following: debridement, decompression, or rotator cuf repair. Signifcant
associations then underwent multivariate analysis, which found that
smoking was an independent risk
factor for any complication/mortality
event in shoulder arthroscopy with
decompression (OR=1.46; 95% CI:
1.030-2.075), shoulder arthroscopy
with debridement (OR=1.933; 95%
CI: 1.211-3.084) and knee arthroscopy

with medial and lateral meniscectomy
(OR=1.97, 95% CI:1.407-2.757).
Preoperative smoking was found
to be an independent risk factor for
complications for several arthroscopic
procedures, though with variability
between types of procedure. In our
study, patients who smoked were
signifcantly younger, and, presumably, healthier. This is a potential
confounder, which may account for
some of the variability in the impact
smoking had on outcomes between
different procedures. Strengths of
this study include the use of a nationally validated database, with a large
sample size and robust clinical characteristics. Limitations include the
retrospective nature of the study,
lack of data on surgical technique
and simultaneous procedures, 30-day
follow up window, and reliance of selfreporting of smoking status.
Overall, our data highlights that
even in generally low-risk arthroscopic
procedures, preoperative smoking may

increase the risk of potentially serious
perioperative and early-postoperative
complications. Our work adds to the
breadth of literature demonstrating
that smoking is detrimental to patient
outcomes in orthopaedic surgery in
both the short- and long-term.
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Atherosclerosis is a common cause
of vertebral artery stenosis leading to
vertebrobasilar or posterior circulation strokes and transient ischemic
attacks (TIA). About 20 % of ischemic
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strokes occur in the vertebrobasilar
circulation.1 Vertebrobasilar circulation perfuses the medulla, cerebellum,
pons, midbrain, thalamus, and occipital cortex. Therefore, atherosclerotic
disease in these vessels can result in
significant multisystem disability
and death. There are two portions
of the vertebral arter y, extracranial (V1 – V3) and intracranial (V4).
Though the extracranial vertebral
artery disease is generally regarded to
have more benign outcomes as compared to intracranial, 50% of these
patients may have a stroke at initial
presentation while another 26% may

present with TIAs.2 For decades, the
primary treatment in these patients
has consisted of antiplatelet and
anticoagulation drugs such as aspirin
and warfarin. However, advances
in endovascular technolog y with
balloon angioplasty or angioplasty
with stent placement have become
efective alternatives. Recent trials
such as the VIST trial have shown
that interventional techniques are
feasible, safe, and efective.3 However,
more evidence is required to reach
a consensus. The aim of the present
Continued on p. 34

33

Continued fom p. 33
study is to compare best medical treatment and the endovascular approach
in terms of stroke and death rates at 1
month and at last follow-up.
We identifed ECVA studies published between January 1966 and
December 2017 using a search on
PubMed. The rates of stroke and
stroke and/or death were estimated
for best medical treatment and endovascular treatment at 1 month and
at last follow-up. A random effects
model was used to calculate pooled
proportions (PP) across studies and
95% confdence intervals. A total of 57
reports were included in the analysis,
eight studies reported outcomes in
patients receiving medical treatment
(362 patients) and forty-nine studies
reported upon patients treated with
endovascular approach (2142 patients).
The mean age of patients in the
medical group was 65.6 years (range
61.3 - 69.0 years) and 64.1 years (range
53.5 - 72 years) in the endovascular
group. The 30-day incidence of stroke
was 26 (7.2%) in the medical treatment group compared to 18 (0.84%)
in the endovascular group, resulting
in a higher risk for patients in the best
medical treatment when compared
to endovascular treatment (p-value
= 0.0001). Similarly, at follow-up, 33
(12.3%) strokes were observed in the
medical group compared to 51(2.4%)
in the endovascular group (p-value
= 0.0001). There was also statistically signifcant diference in stroke
related death in the medical group
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Medical

Endovascular

No of Studies

8

49

No of Subjects

362

2142

Mean Age

65 6

64 1

84

580

Females

TABLE 1: Baseline Characteristics
versus endovascular group 12 (4.5 %)
vs 1 (0.04%) (p-value =0.001). There
was no statistically signifcant diference in rates of TIA or death to other
causes between the two groups.
Our analysis demonstrated that
endovascular treatment signifcantly
reduced the risk of stroke and death
when compared to best medical treatment alone at 30 days and at follow-up.
However, because of the paucity of
long-term outcomes of patients on
standard medical therapy and large
variability observed between endovascular case series, a prospective
randomized trial is warranted in order

to better understand the safety and
efcacy of the endovascular treatment
compared to the standard medical
therapy.
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Medical

Endovascular

Signifcance

# of Peri-Op Strokes

26 (7 2%)

18 (0 84%)

p = <0 0001

# of Strokes at Follow-Up

33 (12 3%)

51 (2 4%)

p = <0 0001

# of Stroke Related Deaths at
Follow-Up

12 (4 5%)

1 (0 04%)

p = 0 001

**Peri-Op = within 30 days

TABLE 2: Outcomes
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The prevalence of diabetes mellitus
(DM) has been rapidly increasing,
contributing greatly to the burden
of disease in patients and increasing
economic costs for the healthcare
system in the United States.1,2,3 Impact
on quality of life after surgical treatment is a signifcant concern for many
diabetic patients.4 While the impact
of DM on various surgical procedures
has been studied, its impact on patient
outcomes following anatomic pulmonary resections remains to be established. Therefore, we conducted this
retrospective analysis to investigate

DEMOGRAPHICS

the impact of insulin dependence on
DM patients undergoing anatomic
pulmonary resections.
The National Surgical Quality
Improvement Program surgical registry maintained by the American
College of Surgeons was queried to
identify patients who under went
pulmonar y resections from 2005
to 2016 by Current Terminolog y
Procedure (CPT) codes. Ultimately,
18,246 patients were included in the
analyses after excluding patients with
missing data. Patients were stratifed
into three cohorts by their diabetes
mellitus status — non-diabetics (NonDM), non-insulin dependent diabetes
mellitus (NIDDM), and insulindependent diabetes mellitus (IDDM).
These cohorts were compared for
differences in their demographics,
preoperative comorbidities, and
complication rates using one-way
analysis of variance (ANOVA) for
continuous variables and Pearson’s
Chi-squared tests or Fischer’s exact
tests (expected cell count < 5) for

Non-DM

%

15,433

NIDDM

%

2,017

categorical variables. Multivariate
logistic regression models were generated with NIDDM and IDDM as
independent risk factors to establish
risk associations between diabetes
mellitus and specifc adverse events
in these patients.
Upon analyzing the preoperative
comorbidities between the three
cohorts, NIDDM and IDDM patients
had significantly higher rates of
dyspnea (p<0.001), chronic obstructive pulmonary disease (p=0.014),
congestive heart failure (p=0.001),
hypertension requiring medication
management (p<0.001), acute renal
failure (p=0.048), dialysis dependence (p<0.001), open wound/wound
infections (p<0.001), hematologic
disorders (p<0.001), and functional
dependence (p<0.001) compared to
non-diabetic patients. The non-diabetic cohort had a signifcantly larger
proportion of smokers (35.51%) than
the NIDDM (30.34%) patients and
Continued on p. 37

IDDM

%

796

Sex

<0 001

Female

8447

54 73%

897

44 47%

340

42 71%

Male

6986

45 27%

1120

55 53%

456

57 29%

Race
American Indian/Alaska Native

<0 001
101

0 65%

14

0 69%

4

Asian or Pacifc Islander

576

3 73%

104

5 16%

20

2 51%

Black or African American

1007

6 52%

173

8 58%

95

11 93%

21

0 14%

1

0 05%

1

0 13%

13728

88 95%

1725

85 52%

676

84 92%

Hispanic
White

P-value

0 50%

TABLE 1A:
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PRE-OPERATIVE COMORBIDITIES
Smoke

5480

35 51%

612

30 34%

245

30 78%

Dyspnea
No Dyspnea

<0 001
<0 001

11934

77 33%

1487

73 72%

567

71 23%

At Rest

265

1 72%

35

1 74%

21

2 64%

Moderate Exertion

3234

20 96%

495

24 54%

208

26 13%

Ventilator Dependence

29

0 19%

0

0 00%

5

0 63%

COPD

3756

24 34%

541

26 82%

216

27 14%

0 014

Ascites

10

0 06%

1

0 05%

4

0 50%

<0 001

Congestive Heart Failure

75

0 49%

16

0 79%

11

1 38%

0 001

Hypertension

0 002

8291

53 72%

1675

83 04%

672

84 42%

<0 001

Acute Renal Failure

15

0 10%

4

0 20%

3

0 38%

0 048

Dialysis Dependent

44

0 29%

14

0 69%

16

2 01%

<0 001

Disseminated Cancer

1130

7 32%

111

5 50%

55

6 91%

0 011

Wound Infection

93

0 60%

23

1 14%

15

1 88%

<0 001

Steroid Use

709

4 59%

82

4 07%

59

7 41%

<0 001

Weight Loss

453

2 94%

57

2 83%

26

3 27%

0 823

Bleeding Disorder

431

2 79%

83

4 12%

51

6 41%

<0 001

Blood Transfusions

46

0 30%

2

0 10%

5

0 63%

0 057

Functional Status
Independent

<0 001
15293

99 09%

1981

98 22%

781

98 12%

Partially Dependent

123

0 80%

33

1 64%

14

1 76%

Totally Dependent

17

0 11%

3

0 15%

1

0 13%

OPERATIVE VARIABLES
ASA Classifcation
1-No Disturb

<0 001
58

0 38%

0

0 00%

1

0 13%

2-Mild Disturb

3146

20 38%

174

8 63%

32

4 02%

3-Severe Disturb

10942

70 90%

1575

78 09%

604

75 88%

4-Life Threat

1284

8 32%

268

13 29%

159

19 97%

5- Moribund

3

0 02%

0

0 00%

0

0 00%

Epidural

20

0 13%

3

0 15%

0

0 00%

General

15385

99 69%

2014

99 85%

793

99 62%

MAC/IV Sedation

5

0 03%

0

0 00%

2

0 25%

Other

5

0 03%

0

0 00%

1

0 13%

Regional

9

0 06%

0

0 00%

0

0 00%

Spinal

9

0 06%

0

0 00%

0

0 00%

Anesthesia Administered

0 065

aValues expressed as Mean ± Standard Deviation
All other values expressed as (%) and N

TABLE 1B:
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IDDM patients (30.78%; p<0.001),
as well as a history of disseminated
cancer (7.32%) compared to either
diabetic cohort (p=0.011; Table 1a-b).
From the multivariate regression
models, NIDDM patients were found
to be at a significantly higher risk
for reoperation (OR 1.349, 95% CI
1.063-1.712, p=0.014) following pulmonary resections when compared
to non-diabetics (Table 2). IDDM
patients were at a signifcantly higher
risk for experiencing pneumonia (OR
1.342, 95% CI 1.033-1.748, p=0.027),
unplanned intubation (OR 1.449,
95% CI 1.063-1.976, p=0.019), ventilator dependence for greater than 48
hours (OR 1.792, 95% CI 1.281-2.507,
p=0.001), acute renal failure (OR
2.888, 95% CI 1.548-5.389, p=0.001),
strokes (OR 2.353, 95% CI 1.184-4.675,
p=0.015), cardiac arrest (OR 1.94,
95% CI 1.086-3.465, p=0.025), and an
extended length of hospital day of at
least 10 days (OR 1.357, 95% CI 1.1201.644, p=0.002; Table 2).
Discussion: Diabetes mellitus
patients had greater risk for numerous
complications than non-diabetics. By
establishing risk associations between
diabetes mellitus and these adverse
outcomes, surgeons are better prepared to handle these potential complications. Targeting glucose levels to
<200 mg/dL in diabetics may lower the
risk for these serious complications.
IDDM patients were at an increased
risk for pneumonia, intubation, ventilator dependence, renal failure,
cardiac arrest, and extended length
of stay, demonstrating the impact of
insulin dependence on surgical complications. Thus, surgeons can better
preoperatively plan for these adverse
events in diabetic patients undergoing
pulmonary resections.
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IDDM

NIDDM

Complication

Odds Ratio (95% CI)

P-Value Odds Ratio (95% CI)

P-Value

Superfcial Incisional SSI

0 699 (0 361-1 354)

0 288

0 835 (0 513-1 360)

0 47

Deep Incisional SSI

1 338 (0 294-6 093)

0 707

0 868 (0 251-2 996)

0 822

Organ/Space SSI

0 615 (0 305-1 240)

0 174

0 90 (0 516-1 570)

0 711

Wound Dehiscence

1 137 (0 140-9 222)

0 905

-

-

Pneumonia

1 342 (1 033-1 748)

0 027

0 965 (0 797-1 168)

0 712

Unplanned Intubation

1 449 (1 063-1 976)

0 019

1 005 (0 791-1 277)

0 966

Pulmonary Embolism

1 004 (0 461-2 184)

0 993

0 825 (0 516-1 321)

0 424

Ventilator Dependence
(48 hours)

1 792 (1 281-2 507)

0 001

0 824 (0 632-1 075)

0 154

Progressive Renal
Insuffciency

0 485 (0 233-1 01)

0 053

0 741 (0 399-1 376)

0 342

Acute Renal Failure

2 888 (1 548-5 389)

0 001

1 219 (0 666-2 229)

0 521

Urinary Tract Infection

0 788 (0 481-1 291)

0 343

0 968 (0 675-1 388)

0 86

CVA/Stroke

2 353 (1 184-4 675)

0 015

1 141 (0 561-2 319)

0 716

Cardiac Arrest

1 94 (1 086-3 465)

0 025

1 148 (0 696-1 894)

0 588

Deep Venous
Thromboembolism

1 532 (0 879-2 671)

0 132

0 964 (0 609-1 526)

0 875

Myocardial Infarction

1 949 (0 961-3 952)

0 064

1 467 (0 867-2 483)

0 153

Post-Operative Blood
Transfusions

0 974 (0 733-1 296)

0 859

0 966 (0 797-1 171)

0 725

Systemic Sepsis

1 353 (0 729-2 513)

0 338

0 977 (0 684-1 394)

0 897

Septic Shock

0 697 (0 410-1 184)

0 182

1 111 (0 717-1 721)

0 639

Return to OR

0 809 (0 602-1 086)

0 158

1 349 (1 063-1 712)

0 014

Extended Length of Stay
(≥ 10 days)

1 357 (1 120-1 644)

0 002

1 089 (0 944-1 258)

0 243

TABLE 2:
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Vocal cord paresis and paralysis are
recognized complications of endotracheal intubation; the effects of
such complications can range from
quality of life changes such as efortful
speaking, vocal fatigue, and loss of
high register, to more severe outcomes
like aspiration pneumonia and complete voice loss.1
We conducted a retrospective
study, approved by the institutional review board of The George
Washington University Medical
Faculty Associates. The charts of 62
patients were reviewed for this study.
Each of these subjects was diagnosed
with vocal fold paresis/paralysis based
on fve assessments: patient history,
subjective rating scales, laryngeal
examination, laryngeal electromyography (EMG), and acoustic/aerodynamic measures.
Subjects were classifed into four
groups based on EMG interpretations of reinnervation or denervation:
mixed, reinnervation, denervation,
and none. Multiple studies have shown
that signs of reinnervation/denervation on EMG are indicative of patient
prognosis; however, the duration of
time between the symptom onset and
EMG test date has also been shown to
be correlated with prognosis.2,3 Thus,
the above groupings, plus the duration
of time between the intubation date

38

Complete Resolution

No Complete
Resolution

T-test

Average Glottal Function
Index (GFI)

2 89

7 66

p= 6 30E-4

Average Physical Exam Score

0

1 52

p= 5 16E-09

TABLE: Differences in Average Post-Treatment GFI and Physical Exam Scores for
Patients With and Without Complete Resolution of Vocal Cord Weakness
and EMG date, were combined to
create a new defnition of prognosis
of each subject’s vocal cord paresis/
paralysis. Using these criteria, a score
was determined for each patient—a
score closer to 2 indicated a good prognosis while a score closer to 0 indicated
a poor prognosis. Data analysis was
conducted on 3 tiers of patients.
Our analyses of all patients showed
that subjects less than or equal to 60
years of age had an average prognosis
score of 1.21 while subjects above
the age of 60 had a score of 0.79; the
difference between these prognosis
values were statistically significant
at p < 0.05. Our results found that
hypertension was the most common
comorbidity seen in patients who
were diagnosed with a post-intubation vocal cord paresis/paralysis.
Results from the second tier of analysis
showed that of all 38 patients from
whom we had post-treatment data
for, only 9 patients (24%) achieved
complete resolution of their vocal cord
paresis/paralysis (defned as a Glottal
Function Index (GFI) of 7 or below
and a physical exam score of 0). The
average age of subjects that achieved
complete resolution was 54.44 years
and the average age of those that did
not completely recover had an average
age of 59.94. A chi-squared analysis
assessing the relationship between age

at intubation and outcomes showed
no statistically signifcant diferences
(p = 0.05). We also found that patients
with complete resolution of their vocal
cord dysfunction had a post-treatment
average GFI of 2.89, which was 4.77
points lower than the average GFI
for patients without complete resolution. This diference was statistically
signifcant at p < 0.05.
This study is one of the first to
use a larger sample of these patients
to analyze trends—using the compiled data we were able to show how
various cofactors can be used to
determine both the initial prognosis
and outcomes of these patients. Our
results should help guide physicians
to better prevent, diagnose, and treat
patients with vocal cord injury due to
intubation.
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This study evaluates whether delivery
provider affects maternal and neonatal outcomes in nulliparous women
with singleton gestation and a normal
second stage of labor.
We performed a retrospective
cohort study of term, nulliparous
women with singleton gestations
and cephalic presentation, who had a
second stage of labor <3 hours in duration at a single institution. Exclusion
criteria were intrauterine feta l
demise, planned cesarean delivery
or suspected major fetal anomaly.
Outcomes were compared by delivery
provider: obstetrician (MD) and certifed nurse midwife (CNM). Primary
outcome was incidence of cesarean
delivery, with maternal and neonatal
outcomes compared secondarily.
We evaluated 427 women: 120 with
CNM providers and 307 with MD
providers. Maternal demographics
significantly differed by maternal
age at delivery, race, hypertension,
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aOR 11 94
(95% CI 1 61-87 62
99 2%
90 9%

100%
80%
60%
40%

aOR NA

20%
0%

2 9%

aOR 0 25
(95% CI 0 03-1 97
3 3%

0 0%

Cesarean
delivery

NSVD
■ MD

0 8%

FAVD

aOR NA
2 9%

0 0%

VAVD

■ CNM

FIGURE: Delivery Methods aOR- adjusted Odds Ratio, CI-confdence interval, NSVDnormal spontaneous vaginal delivery, FAVD- forceps assisted vaginal delivery, VAVDvacuum assisted vaginal delivery
BMI, epidural use, induction, and
gestational age at delivery. There was
a significant difference in rates of
normal spontaneous vaginal deliveries
(NSVD): 99.2% in CNM patients and
90.9% in MD patients. Incidence
of cesarean delivery was 0% in the
CNM group and 2.93% in the MD
group. The CNM group had a lower
incidence of composite maternal
morbidity: 9.17% vs 19.54% in the
MD group. There were no signifcant
diferences in maternal or neonatal
outcomes.
In term nulliparous women with
singleton gestations who had a normal
second stage, delivery provider did
not signifcantly afect the incidence

of cesarean delivery but signifcantly
afected the incidence of normal spontaneous vaginal delivery. Most women
delivered vaginally, with 97.07%
of women in the MD group and
100% in the CNM group. Maternal
demographics signifcantly difered
between the two groups, with older
patients and decreased epidural use
in the CNM group. MD patients
had higher rates of hypertension
and induction, as well as higher BMI
scores. MD and CNM groups had similar maternal and neonatal outcomes
when controlling for confounders.
Continued on p. 39
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Delivery Subtype
CD
NSVD
FAVD
VAVD

IMD (n=307) ICNM (n=120) Ip-value IOR (95% CI)
9 (2 93%)
279
(90 88%)
10 (3 26%)
9 (2 93%)

0 (0%)
119 (99 17%)
1 (0 83%)
0 (0%)

0 0668 (*)
0 0022*
0 3049
0 0668 (*)

Chorioamnionitis

20 (6 51%)

3 (2 50%)

Endometritis

1 (0 33%)

Postpartum
hemorrhage

Ip-value IaOR (95% CI)

Ip-value

NA
11 94 (1 61 – 88 79)
0 25 (0 03 – 1 97)
NA

0 0154*
0 1881
-

NA
11 94 (1 61 – 87 62)
0 25 (0 03 – 1 97)
NA

0 0154*
0 1881
-

0 0986 (*)

0 37 (0 11 – 1 26)

0 1119

0 31 (0 07 – 1 38)

0 1247

0 (0%)

0 9999

NA

-

-

-

20 (6 51%)

6 (5 00%)

0 5563

0 76 (0 30 – 1 93)

0 5576

0 63 (0 23 – 1 73)

0 3715

Transfusion

0 (0%)

0 (0%)

NA

NA

-

-

-

3rd degree lac

12 (3 91%)

2 (1 67%)

0 3669

0 42 (0 09 – 1 89)

0 2565

0 42 (0 09 – 1 92)

0 2641

4th degree lac

1 (0 33%)

0 (0%)

0 9999

NA

-

-

-

At least 1 negative
maternal outcome

60 (19 54%)

11 (9 17%)

0 0096*

0 42 (0 21 – 0 82)

0 0155* 0 38 (0 19 – 0 77)

0 0072*

NICU admission

10 (3 26%)

7 (5 83%)

0 2697

1 84 (0 68 – 4 95)

0 2274

1 87 (0 69 – 5 03)

0 2167

CPAP

13 (4 23%)

8 (6 67%)

0 2962

1 62 (0 65 – 4 00)

0 3002

1 64 (0 66 – 4 06)

0 2859

Sepsis

2 (0 65%)

1 (0 83%)

0 9999

1 28 (0 12 – 14 27)

0 8400

1 30 (0 12 – 14 46)

0 8314

Seizure

0 (0%)

1 (0 83%)

0 2810

NA

-

-

-

HIE

0 (0%)

2 (1 67%)

0 0785(*)

NA

-

-

-

Shoulder dystocia

6 (1 95%)

1 (0 83%)

0 6787

0 42 (0 05 – 3 54)

0 4262

0 43 (0 05 – 3 59)

0 4336

Death

0 (0%)

1 (0 83%)

0 2810

NA

-

-

-

At least 1 negative
neonatal outcome

21 (6 84%)

10 (8 33%)

0 5930

1 24 (0 57 – 2 71)

0 5936

1 26 (0 57 – 2 76)

0 5683

MD- medical doctor, CNM- certifed nurse midwife, OR- odds ratio, aOR- adjusted odds ratio, NA: not enough occurrence for accurate
result; CD- cesarean delivery, NSVD- normal spontaneous vaginal delivery; FAVD- forceps assisted vaginal delivery; VAVD- vacuum
assisted vaginal delivery; CPAP- continuous positive airway pressure; NICU- neonatal intensive care unit; HIE- hypoxic ischemic
encephalopathy
Data are in mean (%)

TABLE: Perinatal Outcomes
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Patent Ductus Arteriosus (PDA)
is a congenital heart abnormality,
afecting up to 80% of all Extremely
Low Birth Weight (ELBW) infants.1
Surgical repair of this cardiac anomaly
renders the Recurrent Laryngeal
Ner ve v u l nerable to iatrogen ic
damage, ultimately inducing vocal
cord paralysis.2 Our objectives were
to determine the clinical compliance
with postoperative screening for vocal
cord paralysis and associated comorbidities in premature infants following PDA ligation. Given that vocal
cord paralysis is a known complication
of PDA ligation, an understanding of
the current screening methodology is
needed for improvement of care.
A three-year retrospective chart
review was performed for all premature infants who underwent PDA
ligation at the Children’s National
Health System pediatric hospital.
Vocal cord palsy, otolaryngology
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postoperative consultations, and
vs. 0.09%, p=0.0013) compared to
comorbidities (voice abnormalities,
those who did not.
feeding difculties, gastrostomy tube
It’s important to note, not all
placement, and supplemental oxygen
patients who post-operatively preat discharge) were extracted from the
sented with symptoms concerning for
charts. Standard statistical methodvocal cord paralysis were sufciently
ology was applied.
evaluated. Additionally, the reported
Seventy-four patients were idenprevalence of vocal cord paralysis
tified (33M/41F; mean [SD] gestamay be underestimated due to the
tional age 25.6
[3.5] weeks). Of
[T]he reported prevalence of vocal cord paralysis
these patients,
17 infants (23%)
may be underestimated due to the lack of otolarynwere diagnosed
with vocal cord
gology evaluation after PDA ligation, highlighting
pa ra lysis; 14
patients (19%)
experienced
the need for a better screening protocol.
left-sided vocal
cord paralysis, 2
patients experienced bilateral vocal
lack of otolaryngology evaluation
cord paralysis, and 1 patient experiafter PDA ligation, highlighting the
enced right-sided vocal cord paralysis.
need for a better screening protocol.
Despite 33 patients (45%) suffering
Premature infants with known vocal
from post-operative voice abnorcord paralysis after PDA ligation
malities, defned as a hoarse or weak
have greater feeding and respiratory
cry, and 48 patients (55%) with docucomorbidities. Therefore, timely diagmented feeding difculties, only 27
nosis may improve discharge planning
patients (36%) were evaluated by
and patient/parent counseling.
otolaryngology for possible vocal cord
REFERENCES:
paralysis. Patients with known vocal
1 Evans N. Diagnosis of patent ductus artecord paralysis had a higher rate of
riosus in the preterm newborn. Arch Dis
gastrostomy tube placement (53% vs.
Child. 1993; 68: 58–61.
12%, p= 0.0003), supplemental oxygen
2 Lee K. Essential Otolaryngology: Head and
(64% vs. 36%, p= 0.0417), and need for
Neck Surgery, 8th edn. San Francisco, CA:
chronic ventilation at discharge (18%
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Our objective in this study was comparing perioperative and functional
outcomes of autologous fascia lata
vs. rectus fascia pubovaginal sling in
female patients with stress urinary
incontinence (SUI).
Autologous fascial pubovaginal
slings (AFPVS) are the most widely
used surgical treatment in patients
with complex SUI.1,2 The majority
of series have reported the use of
rectus fascia grafts.3,4 Despite this
convention, the use of fascia lata
has been described as an alternative with the benefts of minimizing
postoperative pain and theoretically
lowering the risk of abdominal complications such as wound infections.
Furthermore, fascia lata harvest been
used in patients with signifcant central obesity, poor quality abdominal
fascia or with an extensive history of
abdominal surgery.5 Despite potential
benefts, fascial lata sling harvest is
associated with its own set of complication related to morbidity from a
second incision site and concerns with
long term durability.3 To our knowledge, fascia lata slings have never
been assessed in direct comparison
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Fascia lata
pubovaginal sling

Rectus fascia
pubovaginal sling

N=21

N=84

Operative time (min)

84 (±29 1)

81 9 (±28 9)

0 68

Length of stay (hours)

25 (±9 8)

33 7 (±24 3)

0 15

Estimated blood loss (ml)

91 7 (±90 3)

141 6 (±104 2)

0 04

Postoperative complications
Clavien grade 1
Clavien grade 2
Clavien grade 3
Clavien grade 4 or 5

11 (52 4%)
11
1
0
0

41 (48 9%)
25
14
3
0

0 81

Readmission

1 (4 8%)

3 (3 6%)

0 99

Wound complications
Seroma
Wound infections

0 (0%)
0
0

12 (14 3%)
9*
4*

0 12

p-value

*: one patient had both a seroma and a wound infection

TABLE 1: Perioperative Outcomes
with rectus fascial slings. The aim of
the present series is to compare perioperative and functional outcomes of
autologous fascia lata vs. rectus fascia
pubovaginal sling in female patients
with SUI.
Materials and methods: Charts
of all female patients who underwent
AFPVS for SUI from 2012 to 2017 at
a single academic center were retrospectively reviewed. Patients were
divided into two groups: those with
the autologous sling harvested from
the fascia lata (FL group) and those
with the autologous sling harvested
from the rectus fascia (RF group).
Peri-operative and functional outcomes were compared.

Results: Between 2012 and 2017,
105 women underwent pubovaginal
slings: 21 using FL and 84 using RF.
Operative time did not differ significantly between the FL and RF
groups (84 vs. 81.9 min; p=0.68). There
were more wound complications in
the RF group, but this difference
did not reach statistical signifcance
(0% vs. 14.3%; p=0.12). The overall
complications rates were comparable
in the FL and RF groups (52.4%
vs. 48.9%; p=0.81), but the proportion of postoperative complications
Clavien grade ≥ 2 tended to be higher
in the RF group (4.8% vs. 20.2%;
p=0.11). Overall, wound complications
accounted for 29.3% of post-operative
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complications in the RF group (12/41).
The functional outcomes were comparable between FL and RF group,
with similar rates of patients cured
of SUI symptoms at 1 month (82.4%
vs. 76.4%; p=0.74), 1 year (55.6% vs.
63.8%; p=0.76), and the latest followup (66.7% vs. 65.8%; p=0.87).
When compared to rectus fascia
harvest for pubovaginal sling, fascia
lata harvest may decrease perioperative morbidity, especially wound
complications, without compromising
functional outcomes.
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Fascia lata
pubovaginal
sling
N=21
1-month SUI outcomes
Cured
Improved
Unchanged
Worsened
Lost to follow-up
1-month de novo selfcatheterization
Change in post-void residual at 1
month (ml)
1-year SUI outcomes
Cured
Improved
Unchanged
Worsened
Lost to follow-up
1-year de novo selfcatheterization
Change in post-void residual at 1
year (ml)
Last follow-up SUI outcomes
Cured
Improved
Unchanged
Worsened
NA
Last follow-up de novo selfcatheterization
Last follow-up change in postvoid residual at 1 year (ml)
Mean follow-up (months)

Rectus fascia
pubovaginal
sling
N=84

p-value
0 74

14 (82 4%)
1 (5 9%)
2 (11 8%)
0
4

55 (76 4%)
9 (12 5%)
6 (8 3%)
2 (2 8%)
12

3 (17 7%)

21 (28 8%)

0 54

+ 50 9 (±51 5)

+ 20 5 (±104 8)

0 06
0 76

5 (55 6%)
3 (33 3%)
1 (11 1%)
0
13

30 (63 8%)
9 (19 2%)
6 (12 8%)
2 (4 3%)
37

1 (11 1%)

3 (6 4%)

0 51

+ 43 6 (±66 5)

- 7 (±77 8)

0 18
0 87

12 (66 7%)
5 (27 8%)
1 (14 3%)
0
3

48 (65 8%)
17 (23 3%)
6 (8 2%)
2 (2 7%)
11

3 (16 7%)

7 (9 6%)

0 41

+ 46 (±55 4)

+27 4 (±113 5)

0 10

8 5 (±9 5)

14 1 (±15 4)

0 11

SUI: stress urinary incontinence

TABLE 2: Functional Outcomes
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Neuroanatomical morphometric
analysis in childhood temporal and
extratemporal epilepsy reveals patterns of widespread cortical thinning. 1,2 The degree of neocortical
thinning both ipsilateral and contralateral to the focus in epilepsy is associated with poor epilepsy surgery outcome for MRI-normal adult epilepsy
as well as MRI-abnormal childhood
epilepsy.3,4 This project extends upon
previous investigations by looking at
cortical thickness (CT) differences
in a pre-surgical pediatric epilepsy
population with MRI abnormalities.
Sagittal T1-weighted MPRAGE
structural MRI scans were performed
on 25 pediatric epilepsy patients (age
7–17 years) with abnormalities on
MRI. All surface-based morphometric processing and analyses were
conducted using FreeSurfer (FS) 6.0.
A repeated measures ANOVA was
used to examine the efects of focus
(temporal or extratemporal), side
(ipsilateral or contralateral), and lobe
(frontal, temporal, parietal, occipital)
on cortical thickness.
Repeated measures A NOVA
revealed a signifcant efect of lobe
(p<.01) such that Temporal CT>
Frontal CT> Occipital CT> Parietal
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CT. There was also a trend towards
suggesting that thicker ipsilateral CT
significance for the side of focus
is associated with a good surgery out(ipsilateral vs. contralateral) and a sigcome. Here, we observed thinner CT
nifcant interaction between side and
on the contralateral side in patients
lobe (repeated measures ANOVA,
that largely experienced surgical
p=.055; p<.05), indicating that CT by
success. Future research with larger
lobe varied according to whether the
sample sizes could investigate the
patient had a temporal or extratemrelationship between CT and difporal epilepsy focus. On the ipsilateral
ferent types of MRI abnormality and
side, the order of greatest CT by lobe
surgery outcomes.
was: Temporal> Frontal> Parietal>
REFERENCES:
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(2009). Widespread Neocortical Abnortemporal epilepsy groups, we found
malities in Temporal Lobe Epilepsy with
that the temporal lobe was thickest
and Without Mesial Sclerosis. Neuroon the ipsilateral side. This may be
image, 46(2), 353-359.
because the MRI abnormality which
was la rgely
dysplasia conSeizure onset and duration was associated with thintributed to a
th icker CT.
ning of the ipsilateral parietal lobe suggesting that
Seizure onset
and duration
perhaps the parietal lobe is vulnerable to long-term
was associated with
effects of ongoing seizure activity.
t h i n n i ng of
the ipsilateral
parietal lobe
suggesting that perhaps the parietal
3. Bernhardt, B. C., Bernasconi, N., Concha,
L., & Bernasconi, A. (2010). Cortical
lobe is vulnerable to long-term efects
Thickness Analysis in Temporal Lobe
of ongoing seizure activity.
Epilepsy. Reproducibility and Relation to
Additionally, the majority of this
Outcome. Neurology, 74(22), 1776-1784.
sample (84%) were noted to have suc4. Kamson, D. O., Pilli, V. K., Asano, E.,
cessful surgery outcomes, as quantiJeong, J. W., Sood, S., Juhász, C., &
fed by an Engel Class 1 or 2 designaChugani, H. T. (2016). Cortical Thickness Asymmetries and Surgical Outcome
tion post-surgery, a standard metric
in Neocortical Epilepsy. Journal of the
indicating seizure freedom or signifNeurological Sciences, 368, 97-103.
cant reduction. Thus, our results are
in accordance with previous research,
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Although there are reports of the
impact of congestive heart failure
(CHF) on total knee arthroplasty
(TKA) and total hip arthroplasty
(THA), there is a lack of literature
analyzing CHF in hip hemiarthroplasty (HHA) procedures. The main
objective of this study was to evaluate
the efect of CHF on risks for complications following HHA.
T he A mer ica n C ol lege of
Surgeons National Surgery Quality
I m pr o v em ent P r o g r a m ( AC S NSQIP) is a multi-institutiona l
national database tracking 30-day
patient outcomes and complications for surgical procedures. The
ACS-NSQIP database was queried
for all patients who had undergone
HHA from 2005 to 2016. Pearson’s
chi-squared tests and Fischer’s exact
tests were utilized to compare diferences in demographics, comorbidities,
and complication rates. Multivariate
logistic regression analyses were used
to assess the impact of CHF as an
independent risk factor for postoperative complications following HHA.
Si x hu nd red H H A pat ients
(4.08%) had CHF, and this patient
cohort was older (p<0.001) and had a
larger proportion of males (p<0.001).
CHF was found to be a significant
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Operative Variables

IControl I%

ICHF I%

14095

IP-value

600

Days to Operation from
Admission

1 607
± 7 256

2 998
± 4 676

<0 001

Total Operating Time
(Minutes)

79 96
± 43 440

79 00
± 40 680

0 594

Total Hospital Stay
Length (Days)

7 66
± 7 912

11 21
± 11 560

<0 001

Days from Operation to
Death

13 57
± 8 879

10 74
± 8 848

0 004

Days from Operation to
Discharge

6 22
± 7 026

8 24
± 9 621

<0 001

Discharge Destination

<0 001

Home

2821

20 01%

103

17 17%

Other than Home

7803

55 36%

391

65 17%

Not Reported

3471

24 63%

106

17 67%

Care Type

0 561

Inpatient

14024

99 50%

598

99 67%

Outpatient

71

0 50%

2

0 33%

TABLE 1: Surgery Related Variables of HHA in Control vs CHF

patients

independent risk factor for pneumonia (OR 1.55, 95% CI 1.146-2.097,
p=0.004), progressive renal insufficiency (OR 3.277, 95% CI 1.681-6.387,
p<0.001), pulmonary embolisms (OR
2.728, 95% CI 1.256-5.926, p=0.011),
cardiac arrest (OR 3.582, 95% CI
2.128-6.031, p<0.001), extended length
of stay (≥5 days) (OR 1.447, 95% CI
1.218-1.720, p<0.001), readmission (OR
1.294, 95% CI 1.004-1.669, p=0.047),
and mortality (OR 2.189, 95% CI
1.688-2.839, p<0.001). (See Tables 1
and 2.)

This data illustrates that a known
diagnosis of CHF in patients undergoing hip hemiarthroplasty puts
patients at a signifcantly higher risk
of longer hospital stays following
their procedures. Increased length of
stay (LOS) in orthopedic procedures
is associated with increased postoperative morbidity (i.e. deep venous
thromboembolisms1) and increases
the cost burden to the health care
system.2
Continued on p. 46
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Continued fom p. 45
Beyond LOS, this study found that
CHF is an independent risk factor
for developing pneumonia following
HHA. A lower threshold of suspicion
for pneumonia development in the
postoperative period should be maintained for these patients; more aggressive antibiotic prophylaxis may be
considered for CHF patients in HHA.
Additionally, this study found
CHF to be an independent risk factor
for cardiac arrest. The compensatory
beta-adrenoreceptor stimulation of
the heart to increase stroke volume in
the setting of CHF is associated with
increased risk of arrhythmias and
sudden cardiac death (SCD).3 Heart
failure was also found, unsurprisingly,
in this study to be a signifcant risk
factor for post-surgical mortality in
HHA. In the setting of HHA, we
recommend monitoring patients with
a history of CHF with telemetry/EKG
for evidence of ventricular arrhythmias or other risk factors for SCD
prior to discharge and in follow-up
visits. Cardiac function testing prior to
orthopedic procedures such as HHA
may also be warranted.
The current study also found an
increased risk of progressive renal
insufficiency due to CHF prior to
HHA. CHF and kidney disease are
tightly associated.4 Furthermore, there
is evidence to suggest that arthroplasty
is associated with decreased kidney
function.5 Therefore, this finding
raises the concern for the need for
careful review of the use of perioperative and postoperative medication
usage in HHA patients with history
of CHF.
Further studies evaluating the
timing of medical optimization of
CHF before undergoing HHA is
warranted. More specific precautionar y measures must be taken
to preemptively address potential
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Postoperative Complications
Superfcial Incisional SSI

95%
Odds Ratio Confdence
Interval

I

1 725

I

0 625

P-Value

I

I

4 758

0 292

Deep Incisional SSI

1 014

0 358

2 873

0 979

Organ/Space SSI

1 091

0 258

4 608

0 905

Wound Disruption

4 205

0 874

20 234

0 073

Pneumonia

1 55

1 146

2 097

0 004

Unplanned Intubation

1 305

0 751

2 267

0 346

Pulmonary Embolism

2 728

1 256

5 926

0 011

Ventilator Dependence
(>48 hours)

1 032

0 451

2 364

0 94

Progressive Renal Insuffciency

3 277

1 681

6 387

<0 001

Acute Renal Failure

1 653

0 705

3 877

0 248

Urinary Tract Infection

1 064

0 756

1 498

0 722

CVA/Stroke

1 004

0 397

2 539

0 994

Cardiac Arrest

3 582

2 128

6 031

<0 001

Myocardial Infarction

1 622

0 977

2 695

0 062

Blood Transfusions

1 175

0 964

1 431

0 11

Deep Venous
Thromboembolism (DVT)

1 305

0 591

2 883

0 511

Systemic Sepsis

1 353

0 798

2 295

0 262

Septic Shock

1 584

0 817

3 071

0 173

Death

2 189

1 688

2 839

<0 001

Return to Operating Room

1 087

0 722

1 637

0 69

Extended Length of Stay
(≥ 5 days)

1 447

1 218

1 72

<0 001

Readmission

1 294

1 004

1 669

0 047

TABLE 2: Multivariate Analyses Assessing Congestive Heart Failure as an
Independent Risk Factor for Postoperative Complications
complications in order to optimize
favorable outcomes.

3.
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Congenital heart disease is the leading
birth defect, afecting almost 1% of
births each year.1 Moreover, children
who undergo cardiac surgery with
cardiopulmonary bypass (CPB) show
signifcant cognitive and behavioral
impairments. 2 The subventricular
zone (SVZ) in the postnatal/adult
brain is a ver y crucial region for
neurogenesis and it plays an important role in neocortical growth of
the gyrencephalic front lobe during
postnatal life. Our preclinical studies
have shown that CPB insults can
cause a reduction in the neural stem
progenitor cell (NSPC) pool.1 Others
have shown that MSCs promote
neurogenesis from SVZ NSPCs in
early and late rodent models. 2 The
aim of this study was to observe the
impact of mesenchymal stem/stromal
cell (MSC) intra-arterial delivery
through cardiopulmonary bypass
(CPB) on the proliferation of neural
stem/progenitor cells (NSPC) and
neuroblast migration in the porcine
subventricular zone (SVZ).
The porcine SVZ resembles its
human counterpart and therefore
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V-SVZ

FIGURE 1: DCX+ Staining, scale bar: 200 μm
served as the animal model for this
study. Two-week old piglets (n=12)
were randomly assigned to one of
three groups: (1) Control, (2) Deep
hy potherm ic circu lator y a rrest
(CPB/DHCA), and (3) CPB/DHCA
followed by MSC administration.
MSCs (10x10 6 per kg) were delivered
intra-arterially through CPB. The
piglet brains were fxed three hours
post-CPB. NSPC proliferation was
determined by SOX2+ and Ki67+
antibodies. Neuroblast and radial-glia
like cells were identifed by DCX+ and
GFAP+ antibodies. The anterior-SVZ
was divided into three tiers which
were then subdivided into ventral
and dorsolateral SVZ. Quantifcation
of the NSPC and neuroblasts in
each tier/region was performed, as
these parameters refect neurogenic
activity.
CPB/DHCA increased early proliferation of NSPCs. MSC delivery did
not alter CPB-induced increased early

proliferation of NSPCs. However,
MSC delivery reduced the length of
GFAP+ processes of radial-glia like
cells and the amount of DCX+ neuroblasts in tier 1 and increased the density of DCX+ cells in tiers 2 and 3 where
neuroblasts migrate tangentially
toward the frontal lobe. These fndings
suggest that MSC delivery changes
neuroblast distribution within the
SVZ and promotes neuronal migration
toward the frontal lobe.
Our data shows that CPB insults
cause proliferation of SVZ neural
stem/progenitor cells. Moreover, our
preliminary results suggest that MSC
delivery has the potential to affect
migratory stream of young neurons
in SVZ in the acute phase. To determine the ameliorative efect of MSC
delivery on neurogenesis, we will need
to further investigate the SVZ in long
term studies.
Continued on p. 48
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FIGURE 2: DCX+ Dorsolateral Zone Tier 2+3, scale bar 50 μm
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Pre-Surgical vs. Long-Term Follow-Up FMD Percent
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Ruptured abdominal aortic aneurysms (AAA) cause around 175,000
deaths globally per year.1 In the U.K.,
AAA rupture comprises 1% of causes
of death for men over 65 years.2 Several
studies have explored fow-mediated
dilation (FMD) as a biomarker for
endothelial dysfunction, which plays
a key role in the pathophysiology of
aneurysm development. A previous
study from this group (OxAAA), in
fact, found that decreased FMD of
the right brachial artery was correlated with AAA progression; in addition, soon after surgical repair of the
aneurysm, FMD among participants
improved.3 No previous study has
explored whether this improvement
persists long-term, however. The
purpose of this study, therefore, was
to evaluate the long-term changes in
endothelial function of a subset of
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10 n=43
FMD %

The University of
Oxford

n=43

-5 -

I

I

I

I

I

0-

I

Wilcoxon matched-pairs signed rant test
-5

P value

0 0051
I

I

TP-3

TP-F1/F2

FIGURE 1: Pre-surgical FMD values (TP3) vs Post-surgical long-term follow up FMD
values (1 year and 2–4 year follow up combined, TP-F1/F2) Analyzed using Wilcoxon
Sign Rank Test
participants in the previous study.
The study was conducted using the
OxAAA database of participants who
had received either an endovascular
(EVAR) or an open AAA repair at The
John Radclife Hospital in Oxford,
U.K. since 2013. Participants who
had received at least a preoperative
and postoperative FMD evaluation

were included in the study (N=43).
Participants were recalled to the
hospital from May-August 2018 for
follow-up collection of blood samples,
and FMD measurement using highfrequency ultrasound of the brachial
artery. Arterial diameter was measured at baseline, during four minutes
of artery occlusion, and immediately
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Pre-Surgical, Post-Surgical, 10Year, and 2–4 Year Follow-Up FMD Percent
n=13

15

10
n=43
FMD %

after release of occlusion to measure
FMD. The data were analyzed using
the software “Brachial Analyzer,”
and results were compared against
participants’ previous FMD values.
The Wilcoxon Sign Rank Test was
used to compare patients’ FMD values
at two time points (pre-surgical and
1–4-year follow up), while ANOVA
was used to analyze patients’ changes
in FMD over multiple points of follow
up (pre-surgical, post-surgical, 1-year,
and 2–4-year follow up).
Demographic information about
this cohort and FMD protocol has
previously been published;3 this subgroup, however, was 97% male and
100% white, consistent with the UK
epidemiology of AAAs. The average
number of days from surgery to follow
up for participants was 996.7. Analysis
showed a statistically significant
increase in FMD among all 43 patients
between 1–4 years after AAA repair
(p=0.0061) (Figure 1). The following
figure (Figure 2) demonstrates an
increase in FMD at each point of
follow up after surgery for the 13
participants for which all data points
were available; however, the small
sample size limits any interpretation
of statistical signifcance .
Th is st udy demonstrated
improved FMD several years after
AAA repair among patients. These
fndings support the hypothesis that
AAAs are systemic vascular diseases,
and not simply local, abdominal
pathology. The exact mechanism is
unknown at this time. Current vascular research findings present the
aortic thrombus as a possible source
of systemic inflammation; another
U.K. cohort study of AAAs that found
that even small, sub-surgical AAAs
substantially increase the risk of MI

-5

0
Friedman test
P value

-5
TP-3

TP-5

TP-F1

0 0079
TP-F2

FIGURE 2: Pre-surgical FMD values (TP-3), Post-surgical (TP-5), 1-Year Follow-Up (TPF1), and 2–4 Year Follow-Up (TP-F2) FMD % ANOVA Analysis
or stroke among patients.4 If AAA is
indeed a systemic disease, perhaps the
risk of rupture is not the only consideration for timing of surgical intervention. FMD could therefore not only be
used as a cost-efective, reproducible,
and non-invasive biomarker to aid in
determinations of surgical interventions, but may serve as a biomarker
for increased cardiovascular disease
risk. Though the power of this study is
limited, it provides the frst evidence
for long-term improvement in endothelial function after AAA surgery;
further research should build on these
fndings.
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Racial Disparities in Late-Stage Prostate Cancer:
A Seer Database Analysis 2005–15
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Incidence of metastatic prostate
cancer in the United States has
increased over the past ten years, but
it is unknown how this trend varies
over time in diferent racial and ethnic
populations.1 Racial and ethnic disparities in prostate cancer incidence
and mortality are well documented.2,3
Further examination of diferences
in initial rates of prostate cancer
diagnosis by race/ethnicity is needed
to distinguish factors precipitating
disparity.
We identi f ied a l l men f i rst
diagnosed w ith prostate ca ncer
from 2005–15 in the Surveillance,
Epidemiolog y, a nd End Results
(SEER) program of the National
Cancer Institute, which monitors 18
population-based cancer registries.
Yearly cancer diagnosis frequency
from 2005 to 2015 was categorized
and analyzed by stage (in situ/localized, regional, and distant), race/
ethnicity [White, Asian American/
Pacific Islander (A API), Black],
and age group (45–54, 55–69, 70-75).
Chi-squared tests and multivariable
logistic regression models were used
for data analysis with p<0.05 considered signifcant.
In the 10-year study period, the
proportion of regional-stage prostate
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FIGURE 1: Adjusted OR (with 95% confdence interval) for prostate cancer in 200912 and 2013–15 versus 2005–08, stratifed by race Adjusted for age A Distant vs in
situ/localized B Regional vs in situ/localized Horizontal black line shows the odds for
the reference group White, Asian, and Black men’s odds of having an initial diagnosis
of distant prostate cancer, versus in situ/localized cancer, increased by 106%, 84%, and
62%, respectively (p= 001), between the early and late years of the study Their odds
of having an initial diagnosis of regional prostate cancer versus in situ/localized cancer,
increased by 24%, 30%, and 31%, respectively (p= 001)
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cancer increased from 14.2% to 16.6%
of cases (p<.0001) and distant-stage
increased from 3.3% to 5.8% (p<.0001).
The odds of being diagnosed with
regional-stage prostate cancer in
2013–2015 compared to 2005–08
were 1.3 times higher for Black men
(95% CI: 1.2-1.5), 1.3 times higher for
AAPI men (95% CI: 1.1-1.5), and 1.2
times higher for White men (95%
CI.2-1.3) (Figure 1a). The odds of
being diagnosed with distant-stage
prostate cancer in 2013–15 compared
to 2005–08 were 1.6 times higher for
Black men (95% CI: 1.4-1.9), 1.8 times
higher for AAPI men (95% CI: 1.52.3), and 2.1 times higher for White
men (95% CI: 1.9-2.2) (Figure 1b).
In 2005-2008, 2009-2012, and 20132015 respectively, the odds of being
diagnosed with distant-stage prostate
cancer were 1.8 times higher, 1.7 times
higher, and 1.4 times higher for Black
men compared to White men (all
respective p<.0001) (Figure 2a), and 1.5
times higher, 1.5 times higher, and 1.4
times higher for AAPI men compared
to White men (all respective p<.001)
(Figure 2b).
The incidence of late-stage prostate cancer has increased signifcantly
in all U.S. males despite race and
ethnicity. Men from minority groups
experienced higher rates of newlydiagnosed distant-stage prostate
cancer within each year group when
compared to White men, with rates
declining over time. Regional-stage
prostate cancer increased the most
over time in AAPI and Black men,
while newly diagnosed distant-stage
prostate cancer increased the most
over time in White men. Genetic
variation in disease progression, differences in socioeconomic status, and
healthcare access have been posited
as theories for disparities in prostate
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FIGURE 2: Adjusted OR (with 95% confdence interval) for prostate cancer in Black
and AAPI men when compared to White men, stratifed by year Adjusted for age A
Distant vs in situ/localized B Regional vs in situ/localized Horizontal black line shows
the odds for the reference group In 2005–08, 2009–12, and 2013–15, respectively, the
odds of having an initial diagnosis of distant prostate cancer, versus in situ/localized,
were 76%, 68%, and 40% higher for Blacks than Whites, and 53%, 52%, and 37% higher
for AAPI than Whites (p< 001) The odds of initial diagnosis of regional prostate cancer,
versus in situ/localized, were 36%, 28%, and 30% lower for Blacks than Whites (p< 001),
for the respective year groups, while 2009-2012 showed the only signifcantly higher
odds of regional diagnosis in AAPI compared to whites to be 11% higher (p< 05)
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cancer care.2,4,5 Changes in guidelines
for PSA-based screening may be
responsible for this increase, although
this was not directly investigated.
Based on our fndings and previous
studies, we suggest considering racial
and ethnic disparities when developing PSA-based screening guidelines
in an efort to reduce them.2,3
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Developing a Method to Objectively Assess
Sensory Nerve Fiber Sensitivity: A Pilot Study
Tess Whiteside,
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individual with tourniquet-induced
ischemia The tourniquet was
removed at 20 min and effects of
reperfusion were noted at 22 min
A) 5 Hz (at 1 5mA) n-PRDs; nPRD
AUCs were 0 690, 1 900, and 1 04
for baseline, 12 min, and 22 min,
respectively B) n-PRDs from the 2000
Hz (at 1 5mA) stimulus; nPRD AUC
values were 0 505, 0 699, and 0 824
for baseline, 12 min, and 22 min,
respectively
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The rate of chronic pain in the United
States is greater than the combined
rates of diabetes, heart disease, and
cancer, with associated healthcare
costs ranging from $560-$635 billion
per year.1,2 It is imperative that an
objective assessment tool be developed to ensure adequate pain evaluation and appropriate analgesic
intervention is provided to patients
experiencing chronic pain.
Pupillary reflex dilation (PRD)
occurs when an alerting stimulus activates peripheral nociceptive fbers and
elicits pupillary dilation. Preliminary
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FIGURE: n-PRDs from an

data indicates that a unique PRD
(nPRD) can be produced by depolarizing sensory nerves (Aβ, Aδ, and C
fbers) via non-noxious neurospecifc
electrical stimuli at particular frequencies. The amplitude of the nPRD
correlates with pain self-report and
the area under the curve (AUC) of the
nPRD refects nerve fber sensitivity.
These fndings suggest that the AUC
could function as a metric of nerve
fber sensitivity and that the nPRD
has potential utility in objective
assessment of pain characteristics,
including type and intensity.

In this pilot study of healthy
adult subjects, infrared pupillometry
was used to evaluate whether the
nPRD was refective of known differences in nerve fiber physiology
under tourniquet-induced ischemic
conditions. Changes in sensory nerve
fber activity occur in ischemic environments due to factors such as degree
of myelination.3 At a baseline state,
activated, myelinated Aβ touch fbers
inhibit transmission of presynaptic
pain signals by unmyelinated, nociceptive C-fibers to diminish pain
sensation.5 However, in an ischemic
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environment, Aβ fbers are not activated. Thus, there is no suppression
of C-fibers, resulting in stable or
increased pain. It was hypothesized
that this phenomenon could be quantifed by the nPRD AUC for each fber
type and that tourniquet application
would cause decreased Aβ sensitivity
and increased C-fber sensitivity (see
Table).
A baseline electrical stimulus for
each subject was determined by their
perception threshold. For baseline
nPRD measurement, each fber type
was assessed using perception intensity at a specifc activating stimulation
frequency (C fber at 5 Hz, Aδ at 250
Hz, and Aβ at 2000 Hz). A tourniquet
was then placed on the subject’s upper
arm to induce ischemia, and the same
nPRD measurements were repeated
at 5-minute intervals for each fiber
type. The tourniquet was removed at
20 minutes, and fnal measurements
were taken during reperfusion.
In this pilot study, five subjects
demonstrated the hy pothesized
outcome. As demonstrated in the
Figure, at 12 minutes after tourniquet
placement the Aβ nPRD AUC was
diminished while the C-fber nPRD
AUC was significantly increased
from baseline. This suggests that
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Time point

ΔAUC of C-fber (5Hz)

ΔAUC of Aβ fber (2000Hz)

-

-

Before Tourniquet Removal





After Tourniquet Removal





Baseline

TABLE: Expected Change in nPRD AUC for Each Nerve Fiber Type at Different Time
Point
ischemia resulted in removal of Aβ
regulation and disinhibition of the
C-fiber. During the reperfusion
period, the C-f iber nPRD AUC
decreased towards baseline indicating
a return of Aβ suppression. During
this reperfusion period, the Aβ nPRD
AUC increased to refect heightened
sensitivity. For all fve subjects, there
was a signifcant diference between
the Aβ nPRD AUC values (p=0.024)
and a diference trending towards signifcance between the C-fber nPRD
AUC values (p=0.091) at the three
time points.
These results indicate that the
nPRD has potential to detect modulation of nerve fber sensitivity. The
data from subsequent trials will help
determine whether infrared pupillometry in conjunction with selective neurostimulation can be used to
objectively measure and monitor pain.
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Schwannomas are benign tumors of
the peripheral nerve sheath. They frequently occur in the head, neck, and
extremities.1 Schwannomas within
adrenal glands are extremely rare, with
only 42 reports. The majority of cases
have been discovered incidentally
and do not demonstrate increased
incidence in any age group or gender.2
Importantly, despite their association
with the adrenal medulla all previous
cases except for one report no clinical
or biochemical evidence of hormonal
activity.3 Diferentiation of schwannomas from other nonfunctional
adrenal masses (adrenal adenoma,
adrenocortical carcinoma, adrenal
metastasis, adrenal myolipoma, and
neuroblastomas) is challenging and
imaging alone is insufcient.4 Current
guidelines state that the management
of adrenal incidentalomas should
consider the tumor size and associated
symptoms, where masses larger than 6
cm or those causing symptoms should
be resected while masses smaller than
4 cm should be closely followed with
imaging.5
A previously healthy 37-yearold male with no significant past
medical history initially presented to
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his primary care physician with new
Kocher maneuver was performed
onset mild abdominal discomfort
to refect and retract the duodenum
for which he used omeprazole with
and gain access into the retroperitoonly modest relief. An abdominal
neal space. The mass was dissected
ultrasound was obtained and demfree and removed, which required
onstrated a mass in the right-upper
dividing a portion of the right adrenal
quadrant. A subsequent abdominal/
gland. Hemostasis was achieved, incipelvis CT study demonstrated a
sions were repaired, and the patient
heterogenous 4.3 cm mass adjacent
recovered well and was discharged
to the right kidney and abutting the
home two days later without any
inferior vena cava and porta hepatis
complications.
with no evidence of invasion into any
Gross examination of the resected
structures. An ultrasound-guided
specimen demonstrated an encapsutransabdominal biopsy was obtained
lated 48 g mass with a heterogenous
and demonstrated
a spindle cell neoWhile biochemically and hormonally inert,
plasm that was consistent with schwanthese adrenal tumors cannot be defnitively
noma. During his
pre-surgical evaluation, the patient
diagnosed or differentiated from other adrenal
denied headaches,
palpitations, or hismasses without surgical resection and histotory of hypertension.
He had no surgical
pathologic studies.
history; he was only
taking intermittent
omeprazole; he was a former smoker;
tan-white-orange and partially-cystic
and his family history was remarkable
interior. Histopathologic examinafor leukemia, diabetes mellitus, and
tion demonstrated a spindle cell
hypertension. His physical exam was
neoplasm with neural diferentiation
benign, with only a mildly elevated
and areas of high density (Antoni A)
systolic blood pressure and no signifand low density (Antoni B) cellularity
cant fndings on the abdominal exam.
surrounded by adrenal medulla tissue.
Pre-surgical labs were within normal
Im munoh istochem ica l sta in ing
limits. Therefore, surgical resection
demonstrated a mass that was difwas discussed for defnitive diagnosis
fusely positive for S-100 and SOX10;
and treatment.
and negative for CD117/c-kit and
The patient was consented for
HMB-45. Together, these data supa laparoscopic hand-assisted resecport the diagnosis of intra-adrenal
tion of the retroperitoneal mass.
schwannoma.
Upon entering the abdominal cavity,
Adrenal schwannomas are a rare
the mass was easily identified as it
entity that have only been reported 42
protruded anteriorly adjacent to
times in the medical literature. While
the hepatoduodenal ligament. A
biochemically and hormonally inert,
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these adrenal tumors cannot be defnitively diagnosed or differentiated
from other adrenal masses without
surgical resection and histopathologic
studies. Therefore, adrenal incidentalomas pose a clinical challenge as
their discovery requires maintaining
a broad diferential diagnosis which
includes benign schwannomas and
malignant adrenal neoplasms.
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Microsurgical reconstruction via
free tissue transfer (FTT) is the last
option for closure of nonhealing,
lower extremity ( LE) wounds. 1–3
Unfortunately, amputation may be
required even if FTT is successful.
Thus, assessing amputation risk
before reconstruction would help surgeons profle patient risk and direct
salvage eforts with outcome-expectations. However, there is a paucity
of literature regarding microsurgical
outcomes in chronic wound patients.
The purpose of this study was to evaluate risk factors for major amputation
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following LE FTT for closure in a
chronic wound population.
Between April 2011 and January
2018, 135 LE FTT procedures were
performed by the corresponding
author for soft tissue coverage of
nonhealing wounds. We studied the
relationship of patient demographics,
wound characteristics, and perioperative traits with limb-salvage and
ambulation rates.
Overall microsurgical success was
96.3% (130/135) and limb salvage rate
was 86.7% (117/135). Comorbidities signifcant for amputation were diabetes
(p=0.009), COPD (p=0.002), ESRD
(p=0.007), and PVD (0.02). Only hindfoot wound-location was signifcant
for amputation (p=0.006). Signifcant
perioperative traits included elevated
platelet count on day of closure (332.8
vs 257.8, p=0.01) gracilis f lap-type
(p=0.03). Infectious complication was
the only postoperative complication
predictive of amputation (p=0.007).
By h ig h l ig hti ng patient a nd
perioperative traits that increase
risk of amputation, these data help

clinicians foreshadow the trajectory
of wound closure and limb salvage.
Furthermore, these results are a
first-step to creating protocolized
risk-stratifcation recommendations
for patients undergoing LE FTT for
complex, nonhealing wounds. To
this end, future work will include risk
analysis for individual risk factors.
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medical education:

Sustainable Development Goals and Mental Health
Knowledge Among First Year Medical Students
Most people with mental health
problems want to have paid
employment

-

I

IX

If a friend has a mental health problem,
I know what advice to give them to
professional help
Medication can be an effective treatment
for people with mental health problems
Psychotherapy can be an effective
treatment for people with mental health
problems
People with severe mental health
problems can fully recover
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Most people with mental health
problems go to a health care
professional to get help
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FIGURE 1: MAKS Results of First-Year MD Student Baseline Knowledge of Mental Health Biopsychosocial Factors
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The United Nations Sustainable
Development Goals for 2030 highlights the impact of mental health
illnesses by including goals for the
prevention and treatment of behavioral, developmental, and neurological
disorders.1 One way to measure the
progress of these goals is to monitor
a foundational indicator such as
mental health literacy among medical
students. This study aims to look
specifically at first year medical
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students (MS1s) to determine their
mental health knowledge, as well as
their attitudes towards mental health
biopsychosocial factors.
Fifty-nine frst-year medical students at the George Washington
University School of Medicine and
Helath Sciences were selected to participant in this study prior to the onset
of the behavioral sciences section of
the curriculum, allowing the assessment of baseline knowledge. The frstyears underwent a baseline assessment, an intervention to introduce
negative mental health outcomes, as
well as a post intervention assessment.
The baseline assessments included the
Mental Health Knowledge Schedule
(MAKS) and the Attitudes Towards
Seeking Professional Psychological
Help Scale (ATSPPH). MAKS is
designed to assess confdence of one’s
knowledge of the biopsychosocial

factors of mental illness, as well as
the ability to identify terms that are
defned as mental illnesses under the
Diagnostic and Statistical Manual of
Mental Disorders, 5th Edition (DSM5). 2 ATSPPH assesses perceptions
towards mental health biopsychosocial factors, also making it ideal as a
post intervention assessment.3 The
program intervention itself aimed to
introduce students to negative mental
health outcomes such as demoralization, burnout, depression, and dependency; as well as the diferent strategies that can be applied to address
the diferent negative mental health
outcomes.
While this investigation looks at
many factors, there are three main
fndings that merit the greatest attention. The frst is that there is great
discordance to the statement “Most
people with mental health problems
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FIGURE 2: MAKS Results of First-Year MD Student Baseline Identifcation of Mental Health Disorders
go to a healthcare professional to get
help.” This implies that among MS1s
there is either a gap in knowledge or
misinformation about the epidemiology of mental health care services.
The second finding is that drug
addiction and depression responses
lack the unanimous agreement to be
identifed as a mental illness. This is
concerning because these are classic
DSM-5 defnitions, which points to
the possibility of biases that students
may hold. The third fnding is that the
intervention showed mixed results in
shifting students’ attitudes towards
positive statements about mental

health biopsychosocial factors. This
implies that the intervention must be
modifed in order to address why some
students had their attitudes shifted
towards the negative.
In conclusion, the combination of
the MAKS survey, ATSPPH survey,
and the program intervention demonstrates a mix in baseline knowledge
and attitudes in mental health knowledge among MS1s. These results identify the knowledge gaps that should be
flled in mental health curriculums,
particularly about which disorders fall
under the DSM-5, as well as the epidemiology of mental health services.

REFERENCES
1.

United Nations. (2015). Transforming
our World: The 2030 Agenda for Sustainable Development .:. Sustainable
Development K nowledge Platform.
Retrieved March 1, 2018, from https://
sustainabledevelopment.un.org/post2015/
transformingourworld/publication

2. Evans-Lacko, S. (2010). Development and
Psychometric Properties of the Mental
Health Knowledge Schedule. The Canadian Journal of Psychiatry, 55(7), 440-448.
doi:10.1177/070674371005500707
3.

Elhai, J. D. (2008). Reliability and validity
of the Attitudes Toward Seeking Professional Psychological Help Scale-Short
Form. Psychiatry Research, 159(3), 320329. doi:10.1016/j.psychres.2007.04.02

•
USIONI---Fusion is the annual, student-run scientifc journal of The George Washington
University School of Medicine and
Health Sciences William H. Beaumont
Medical Research Honor Society.

A student-led

research pub
lica

tion of the Geo

rge Washin

gton Univer

sity School

of Medicine

and Health

Sciences | Spr

Fusion was created to showcase medical
student achievements in basic science
and clinical research, clinical public health,
medical education, and global health
research. Submissions are requested from
medical students annually in the fall.

F[?USi•ON

TThe
hhonoR
The
William
BeaumonT
medical
ReseaRch
honoR
socieTy
he
W illiam
h.
B eaumonT
medical
Re seaRch
onoR
so ci eTy
The
William
h.h.
BeaumonT
medical
ReseaRch
honoR
socieTy

ng 22009
v.
, spRi
009
v. iii
iii,
spRing

THE STUDENT-RUN SCIENTIFIC JOURNAL OF THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES
T HE W ILLIA M H. BEAU MONT M EDICA L R ES EA RC H HONOR SOC IETY

V. IV, SPRING 2010

RNA Interference
in Virus Induced
Hepatitis C
and the Silencing
Mechanism of Tumor
Suppressing Genes, p.6
v. iii, spRing 2009

Dynamic Stabilization
for the Treatment of
Degenerative Spinal
Disorders, p.11
Variables Associated
with the Acceptance
of Acupuncture among
Children with Cancer:
Interim Analysis of a
Prospective Study, p. 16
a student-run scientifc Journal serving The george Washington university medical center

A STUDENT-RUN SCIENTIFIC JOURNAL SERVING THE GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER

A Student-run Scientifc Journal Serving The George Washington University Medical Center
Fusion • 2007

THE WILLIAM H. BEAUMONT MEDICAL RESEARCH HONOR SOCIETY, VOL. V, SPRING 2011

1

.

Fusi.oN

FUSION ,:

A student-led research publication of the George Washington University School of Medicine and Health Sciences | Spring 2016, Volume IX

THE STUDENT-RUN SCIENTIFIC JOURNAL OF THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

.. -B _~~

\ ...,1
{

J>

•

.

·◄

THE WILLIAM H. BEAUMONT MEDICAL RESEARCH HONOR SOCIETY, VOL. VII, SPRING 2014

A student-led research publication of the George Washington University School of Medicine and Health Sciences | Spring 2017, Volume X

A student-led research publication of the George Washington University School of Medicine and Health Sciences | Spring 2018, Volume XI

ing 2019, Vol

ume XII

